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Summary 
The focal adhesion kinase (FAK) is well characterized non-receptor tyrosine 
kinase, although it undergoes also to phosphorylation on serine residues whose 
role is not fully understood. FAK is ubiquitously expressed and plays a crucial 
role as integrator of signaling from either integrins or Receptor Tyrosine 
Kinases (RTKs) and has been linked to cell transformation and progression in 
many solid tumors. Among those, the Epithelial Ovarian Cancer (EOC) has a 
different behaviour during progression: it rarely metastasizes to distant sites but 
disseminate within the peritoneal cavity.  
Our attention was focused on the characterization of the role of FAK in 
different type of tumor cells and in particular on the phosphorylation (P) on the 
serine 732 of FAK (P-FAKSer732). We found that P-FAKSer732 was present 
at variable levels in cancer cell lines but its activation was independent from 
integrin engagement and from the kinase activity of FAK. P-FAKSer732 was 
not localized at the focal adhesion site during migration but it was accumulated 
in dividing cells, co-localizing with the tubulin of the spindle during mitosis 
and regulating microtubule (MT) polymerization and mitotic spindle formation. 
CDK5 was identified as the specific kinase responsible for FAK serine 
phosphorylation whose activation was induced by EGF stimulation of the 
EGFR/ERK signalling. Thus, we have identified for the first time the axis 
EGFR/MEK/ERK/CDK5/P-FAKSer732 as a novel pathway leading to mitosis 
of tumor cells.  
We next aimed to identify the mechanism governing the crosstalk between 
adhesion molecules and RTKs thus leading to proliferation, migration and 
invasion of tumor cells. I focused my analysis on EOC which is the main cancer 
histotype studied in our laboratory. We therefore investigated in EOC cells a 
possible role of E-cadherin (cadh) to contribute to the novel signalling pathway 
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described above. Indeed, we found that E-cadh was the adhesion molecule 
necessary for the formation of the EOC multi-cellular aggregates (MCAs) 
present in the ascites. The E-cadh and CDK5 resulted to be necessary to the 
generation of FAKSer732 and this protein complex was necessary for the EGF-
mediated EGFR activation likely due to the stabilization of EGFR protein on 
the cell membrane. In line with these results, E-cadh expressing EOC cells were 
more susceptible to the CDK5 inhibitor, roscovitine. These data demonstrated a 
pivotal role of E-cadh in contributing to the proliferation of EOC MCAs. 
To clarify the processes responsible for the switch from a proliferative to a 
more invasive phenotype of EOC MCAs necessary for tumor dissemination, we 
were studied another RTK, Axl whose expression has been already reported to 
be associated to a more invasive phenotype. We found that the stimulation of 
Axl by its ligand Gas6 required the engagement of β3-integrin with components 
of the extra-cellular matrix (ECM). The crosstalk between Gas6/Axl and the 
integrin signallings was independent by FAK but required the contribution of 
p130Cas, a scaffold protein involved in the transmission of the ECM-integrin 
signalling, for adhesion, migration and invasion of EOC cells. Indeed, the lack 
of p130Cas decreased the level of Gas6-dependent Axl activation and inhibited 
Gas6-induced EOC cells adhesion, migration and invasion. In 56 out of 72 EOC 
biopsies, Axl and p130Cas were significantly co-expressed indicating of a 
collaborative signaling between Axl and p130Cas also in vivo. We have 
identified an Axl signalling which requires a p130Cas-mediated crosstalk with 
integrins for the dissemination of EOCs. Altogether, our investigation allowed 
the definition of two novel adhesion-dependent signalling pathways which 
drive the proliferation and the invasion of EOC cells, respectively. The 
inhibition of these pathways will likely affect EOC MCA growth as well as the 
invasion of EOC solid primary and secondary lesions. 
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Introduction 
 
1. The Focal Adhesion Kinase  
Focal adhesions (FAs) are sites where cells contact the extracellular matrix 
(ECM). The interaction between cells and ECM is possible through specific 
transmembrane proteins, the integrins, and various cytoskeletal scaffold and 
signaling protein that connect the ECM to the actin cytoskeleton. FAs are 
highly dynamic structures that grow or shrink due to the turnover of their 
component proteins (2). The main protein involved in the control of the FAs 
turnover is the Focal Adhesion Kinase (FAK). 
Since its discovery, FAK has been emerging as an important player in both 
normal development and cancer. 
 
1.1 FAK structure 
FAK is a non-receptor tyrosine kinase discovered in the 90’ by two converging 
line of research: as a 120 kDa protein localized at the FAs and tyrosine-
phosphorylated upon integrins clustering and src activation (3, 4). FAK is 
expressed in most tissues and its sequence is highly conserved across species. It 
is composed by a N-terminal FERM (erythrocyte band four.1-ezrin-radixin-
moesin) domain; a 40 amino acid linker domain; a  central tyrosine kinase 
domain; a C-terminal domain which is responsible for the FAK targeting at the 
FA (FAT domain); and a prolin rich region localized between the kinase and the 
C-terminal domain (Fig.1).  The FERM domain, the FAT domain and the 
proline rich region are docking site for other molecules that belong to the FAK 
signaling. The FERM domain docks also with catalytic domain to auto-inhibit 
the kinase activity (5).  
FAK activation occurs upon integrin engagement with the ECM through an 
ordered sequence of events, starting from the auto-phosphorylation of FAK on 
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tyrosine 397 (Tyr397), achieved by the interaction between the FERM domain 
with activators such integrin β cytoplasmic domain or growth factor receptors 
(RTKs). The full catalytic activation is achieved by binding of src to the 
phosphorylated FAKTyr397 leading to the subsequent phosphorylation of FAK 
on Tyr576 and Tyr577. Those phosphorylation events are followed by the 
recruitment of FAK-binding proteins. In the N-terminal linker region, 
phosphorylation of Tyr397 appears to be important for the recruitment of other 
SH2-containing proteins, including the 85 kDa subunit of phosphoinositide 3-
kinase (PI3K), phospholipase C (PLC)-γ and the Grb2-SOS complex (6-8). The 
C-terminal domain harbors multiple protein-protein interactions sites. In 
addition to the paxillin-binding site in the FAT domains, the proline-rich region 
is recognized by the SH3 domain of p130Cas, a multi-functional adaptor 
protein (9). FAK-induced phosphorylation of p130Cas leads to membrane 
ruffling, lamellipodium formation and actin reorganization. The C-terminal 
region of FAK contains also several serine residues but their role is poorly 
understood.  
 
1.2 Serine phosphorylation of FAK 
Beside the Tyr phosphorylation, FAK is also phosphorylated on serine (Ser) 
residues but just little is known about their function and the role of the Ser 
phosphorylation of FAK has never been studied in cancer. Five major serine 
phosphorylation sites are located in the C-terminal domain of FAK 
corresponding to serine residues 722, 732, 840, 843 and 910 (10, 11). The Ser 
phosphorylation of FAK seems to play an important role during mitosis. The 
cell rounding up at the early stages of mitosis is achieved by the tyrosine de-
phosphorylation of FAK which inhibit FAK/src interaction, and Ser 
phosphorylation of FAK which inhibit FAK/p130Cas interaction. The 
phosphorylation of FAK on Ser residues inhibits also its interaction with β- 
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integrin (12). The phosphorylation on Ser722, which is induced by GSK3-β was 
identified as the responsible for the inhibition of the kinase activity of FAK 
(13), and for the distruption of the interaction with the scaffold protein p130Cas 
(10). The Ser-phosphorylated FAK allows the detachment of cells from the 
substrate and the rounding up necessary for mitosis. At the end of mitosis, the 
cell spreading is achieved by the dephosphorylation of FAK on Ser722 by PP1 
(13).  
Fig.1 FAK structure (5). 
 
RTKs ligands, such as PDGF, FGF and EGF, induce the phosphorylation of 
FAK on Ser910 by ERK (14). The phosporylation of FAK on Ser910 is coupled 
with a reduced binding to paxillin and with the release of FAK from the FAs. 
In migrating neurons, phosphorylation of FAKSer732 (P-FAKSer732) by 
CDK5 regulates MT stability thus pulling the proximal region of the nucleus 
into the leading process, likely in the direction of the centrosome (11, 15).  In 
endothelial cells (EC), VEGF-induced activation of the Rho-dependent kinase 
(ROCK) leads to phosphorylation of FAKSer732 that is crucial for the 
phosphorylation of FAKTyr407 promoting cell migration (16). A new function 
for FAK has been shown in the regulation of centrosome functions in a Ser732 
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phosphorylation-dependent manner during mitosis. Deletion of FAK in primary 
ECs causes increases in centrosome numbers, multipolar and disorganized 
spindles In this case the kinase responsible for P-FAKSer732 was CDK5 (17). 
In pancreatic β-cells, the CDK5/P-FAKSer732 signaling is associated with cell 
survival via the activation of the PI3K/Akt pathway (18). 
 
1.3 FAK function in normal cells 
FAK expression is required in several tissues for normal development and 
solves a pivotal role during embryogenesis: FAK gene knockout in mice 
resulted in an embryonic lethal phenotype. FAK sequence is conserved among 
the species and is expressed in many cells where it is involved in proliferation, 
survival and migration.  
 
1.3.1 FAK regulation of cell proliferation and survival 
FAK regulates cell proliferation. In NIH3T3 fibroblasts over-expression of 
wild-type FAK promotes cell proliferation inducing the exit from the G1 phase. 
FAK promotion of cell cycle progression in NIH3T3 cells requires integrin 
engagement and ERK activity (19). It has been shown that FAK induces the 
expression of the KLF8 transcription factor and promotes cyclin D1 
transcription through the binding of KLF8 to the GT box in the cyclin D1 
promoter. FAK favors cell survival through the degradation of p53. This 
function is solved by the nuclear enriched FAK. The N-terminal region of FAK, 
the FERM domain, can be modified by the addiction of the small ubiquitin-
related modifier (SUMO) at lysine-152 (20). This SUMOylated FAK is 
localized at the nucleus where it binds to Mdm2 and p53 enhancing the Mdm2-
dependent p53 ubiquitination (21). The nuclear FAK is also able to control the 
expression of specific genes, for example the genes that encode mesenchymal 
markers in the TGF-β-induced Epithelial to Mesenchymal Transition (EMT) 
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(22). Another FAK-dependent mechanism of cell survival was shown in 
epithelial and endothelial cells and involves the activation of the PI3K/Akt 
pathway. The phosphorylation of FAK on Tyr397 creates a potential binding 
site for the SH2 domains of the p85 subunit of PI3K (23). Phosphorylation of 
the PI3K subunit, p85, by FAK may activate the p110 catalytic subunit and the 
PI3K/Akt signaling pathway leading to cell survival. In fibroblasts, FAK 
mediates the β1 integrin/PI3K/Akt survival signal in collagen matrices. Thus 
integrin-ECM ligation may activate FAK and promote an adhesion-dependent 
survival signaling through the FAK/PI3K/Akt axis (24).  
 
 1.3.2 FAK regulation of cell migration 
Cell migration is a dynamic and multistep process bringing to rapid changes in 
the dynamics of actin filaments, together with the rapid assembly and 
disassembly of the FAs. In this contest, FAK could be activated by both 
integrins and RTKs and acts as a mediator of the signaling that leads to the 
actin cytoskeleton remodeling and cell migration.  
Upon integrin engagement with the ECM, FAK is recruited to the site of FAs 
and is autophosphorylated on Tyr397 which creates a high-affinity SH2 binding 
site for cellular src. Consequently, src phosphorylates additional tyrosines of 
FAK which in turn, causes maximal FAK kinase activity and phosphorylation 
of p130Cas by the FAK/src complex. Migration requires change in the actin 
cytoskeleton such as membrane ruffling. Tyrosine phosphorylated p130Cas 
associates with several SH2-containing proteins including Crk. The Cas/Crk 
complex formation plays a key role in regulating membrane ruffling and cell 
migration through DOCK180 and Rac. Paxillin is another adaptor molecule 
which has been linked to the FAK signaling. Paxillin is also a major substrate 
of FAK/src kinase complex and its phosphorylation at Tyr31 and Tyr118 
residues could function to recruit Crk in a similar manner as p130Cas (5). 
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Recently, it has been reported that inhibiting FAK/paxillin interactions led to a 
complete loss of FAK localization at FAs together with reduced 
phosphorylation of FAK and FAK targets such as paxillin and p130Cas. In turn 
this resulted in altered FA dynamics and inhibition of cell adhesion, migration 
and invasion (25). FAK is also able to interact directly with small GTPase 
proteins such as Rho, Rac, Cdc42 or can also stimulate their activation or 
inactivation via the association with both, Guanine Exchange Factors (GEFs) 
and GTPase activating proteins (GAPs) which in general, GEFs activate, while 
GAPs inactivate RhoGTPases (26). For example, FAK regulates RhoA 
activation by the phosphorylation and activation of p190RhoGEF (27). FAK 
can also phosphorylate N-WASP, a Cdc42 downstream effector, inducing its 
cytoplasmic localization and activation of the Arp2/3 complex for actin 
polymerization at the leading edge of migrating cells (28). FAK interaction with 
PI3K could stimulate cell migration through its downstream effector Rac, 
which is a key regulator of cortical actin and lamellipodia in cell migration (5). 
Cell migration requires also the disassembly of FAs. Phopshorylation of FAK 
on Tyr925 by src has been linked with FAK loss from focal adhesions and FAs 
disassembly (5). 
  
1.3.3 FAK, microtubules and mitosis. 
Cell migration is a very complex process. To migrate directionally, cells need to 
assemble and disassemble their FAs. The FA life cycle involves the formation 
of integrin-mediated nascent adhesions at leading edge, which either rapidly 
turn over. Actomyosin-mediated pulling forces allow a subset of these nascent 
FAs to grow and mature, and provide forward traction forces. At the rear of the 
cell, FAs also have to release and disassemble (29). An interesting link between 
FAK and microtubules (MTs) has emerged since MTs play an important role in 
controlling FA turnover. 
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MTs are rigid hollow rods highly dynamic characterized by dynamic instability, 
in which individual microtubules alternate between cycles of growth and 
shrinkage. They are involved in cell movement, cell shape, intracellular 
transport, and mitosis. 
A reciprocal regulation exists between FAs and MTs. For example, in migrating 
goldfish fibroblasts, MTs targeting to FAs induces FA disassembly 
demonstrating that MTs may control FA turnover (30). MTs at FAs go through 
growth-to-shortening transitions five times more frequently respect to other 
sites in the cytoplasm, and this also involves paxillin (31). 
The MTs growth-to-shortening transitions is named catastrophe. It could be 
dependent on the availability of free tubulin or be induced by polymerization of 
the MTs against an obstacle. Usually also the presence of catastrophic factors, 
as stathmin, are necessary. Thus, it has been proposed that the density of the 
plaques at the FAs could exert two effects: it is not accessible to free tubulin 
and is a physical obstacle. Paxillin, in this contest, could act as scaffold protein 
for catastrophic factors leading to MT depolymerization (31). Paxillin is 
phosphorylated by FAK, therefore is not weird that FAK could exert a role in 
MT catastrophe at the adhesion site. 
In fibroblasts, integrin-mediated activation of FAK at the leading edge is 
required for MT stabilization by the Rho-mDia signaling pathway (32). On the 
other hand, FAK phosphorylation on Tyr925 and the subsequent recruitment of 
Grb2 and dynamin into a complex with FAK are required for MT-induced 
disassembly of FAs (33).   
The most important changes in cell shape happen during mitosis.  The mitosis 
and the formation of the mitotic spindle, the MT composed-structure necessary 
for chromosome segregation into the two daughter cells, involve deep 
reorganization of the component of the cytoskeleton with the destroy of the 
actin framework and FA disassembly with subsequent cell rounding up (34). 
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During mitosis, the integrin signaling is necessarily inactivated by the serine 
phosphorylation and tyrosine dephosphorylation of protein of the FAs, such as 
FAK, p130Cas and paxillin (12).  
In ECs, deletion of FAK causes an increased in centrosome numbers and 
mitotic spindles defects during mitosis. Transfection with FAK mutated on 
different phosphorylation sites, demonstrated that P-FAKSer732 is involved in 
mitotic spindle regulation and present at the centrosome co-localized with γ-
tubulin. Indeed, P-FAKSer732 was found associated with the MTs motor 
protein dynein (17). 
 
1.4 FAK in malignant cells 
As reported above, FAK is known to have a pivotal role in the regulation of cell 
adhesion, motility, proliferation, and survival in normal cells. Deregulation of 
FAK, usually correlated with an increased protein expression, has been 
implicated in cancer.  
 
1.4.1 FAK in proliferation of tumor cells  
Over-expression of FAK has been linked with tumor proliferation. Recently, in 
breast cancer, it has been found that FAK signaling can occur in the nucleolus 
where it protects nucleostemin, a nucleolar-localized protein which modulates 
cell cycle progression, inducing tumor growth (35). NISCH which encodes the 
imidazoline receptor Nischarin, inhibits FAK-induced tumor growth and 
metastasis in ovarian cancer, and it is usually inactivated by hypermethylation 
(36). FAK and insulin-like growth factor receptor-1 (IGF-1R) directly interact 
with each other and thereby activate crucial signaling pathways that benefit 
cancer cells. Inhibition of FAK and IGF-1R function has been shown to 
significantly decrease cancer cell proliferation and to increase sensitivity to 
chemotherapy and radiation treatment in melanoma (37). In transgenic mouse 
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model of ErbB2-expressing breast cancer, the inactivation of FAK reduced the 
proliferative potential of ErbB2 mammary tumour cells but is dispensable for 
ErbB2 mammary tumour induction in vivo. FAK-null ErbB2 tumours still 
expressed the FAK-related Pyk2 kinase that could substitute FAK in cancer 
progression (38).The integrin β1/FAK axis is necessary for the initial 
proliferation of micrometastatic cancer cells disseminated in the lung. Infact, 
proliferation of these cells is reduced upon FAK knock-down (39). In 
glioblastoma cells, FAK-induced cyclin D1 expression depends on the 
phosphorylation of FAK on Tyr397 and requires ERK in a integrin-independent 
way (40). 
Cell detachment from ECM leads to a specific programmed cell death named 
anoikis. An increased expression of FAK or an uncontrolled function has been 
reported to be involved in the escape from anoikis and the anchorage-
independent growth observed in cancer. In fact, FAK suppresses anoikis in 
pancreatic adenocarcinoma cells (41). In ovarian cancer, it has been reported 
that tumor cells exposed to either norepinephrine or epinephrine exhibit lower 
levels of anoikis due to activated FAK (42). 
  
1.4.2 FAK in migration and invasion of tumor cells  
The process of metastasis formation is a key step in cancer progression and 
requires the capability of tumor cells to migrate and invade by the degradation 
of the ECM through the expression and the activation of the metalloproteases 
(MMPs). In v-src transformed cells, FAK induced src-mediated 
phosphorylation of endophilin A2 decreased its interaction with dynamin, 
which is important in the endocytosis of the cell surface matrix metalloprotease 
MT1-MMP (43). The accumulation of MT1-MMP at the cell membrane leads 
to invasion. The association of FAK with p130Cas also promotes the expression 
of MMP2 and MMP9 via Cas-Crk-Dock180 signaling cascade and activation of 
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Rac1 and JNK as well as their secretion into microenvironment of cancer cells. 
In different cancer cell lines, it was shown that MT1-MMP dependent 
degradation of ECM at the sites of FA requires the formation of a 
FAK/p130Cas/MT1complex. The distruption of the FAK/p130Cas/MT1 
complex significantly impairs FA-mediated degradation and tumor cell invasion 
but doesn’t affect invadopodia formation (44). 
In liver cancer cell migration and invasion is induced by FAK/AKT-mediated 
MMP-2 and MMP-9 production and activation (45). 
Several reports correlate FAK activity with the EMT that is a hallmark of 
cancer. 
In colon cancer cells, expression of FAK mutants that cannot be phosphorylated 
by src induced the disruption of E-cadherin (cadh)-based cell contacts.  
FAK is an important regulator of ECs, neutrophil, platelet, macrophage and 
fibroblast signalling in the tumour microenvironment. In ECs, FAK controls 
vascular permeability and tumour intravasation and extravasation leading to 
metastasis. FAK activity affects macrophages and fibroblasts recruitment to the 
tumour site. FAK promotes spreading, adhesion and survival of stromal cells, 
with concomitant regulation of ECM synthesis or remodelling to promote 
tumour progression (reviewed in (46)). 
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2. RTKs 
Growth factors and their receptors are the core components of signal 
transduction pathways. The majority of growth factor receptors are composed 
of extracellular, transmembrane, and cytoplasmic tyrosine kinase domains. 
RTKs are a large family of transmembrane proteins with heterogeneous 
extracellular regions and common highly conserved intracellular tyrosine kinase 
domain. The binding of extracellular ligands triggers receptor dimerization and 
activation of the receptor's kinase activity leading to the recruitment, 
phosphorylation, and activation of multiple downstream signaling proteins, 
which ultimately change the physiology of the cell. RTKs are divided into 20 
families by amino acid sequence identity within the kinase domain and 
structural similarities within their extracellular regions. In normal cells, RTK 
activity is strictly regulated; but dysregulation or constitutive activation of 
RTKs has been found in a wide range of cancers. The deregulated activation 
occurs by gain-of-function mutation, gene rearrangement, gene amplification, 
over-expression or abnormal autocrine, endocrine or paracrine stimulation of 
both receptor and ligand (47). Since RTKs have been implicated in many 
aspects of the malignant phenotype, they are emerging as promising therapeutic 
targets. Among them, we studied two RTKs which are usually deregulated in 
cancer: The EGFR which belongs to the ErbB family and the Axl receptor 
which belongs to the TAM family  
 
2.1 The EGFR receptor 
The Epidermal Growth Factor Receptor (EGFR) is a transmembrane 
glycoprotein receptor that belongs to ErbB family. ErbB family comprises four 
members named: erbB1/EGFR/HER1, ErbB2/HER2/Neu, ErbB3/HER3 and 
ErbB4/HER4. They share a common structure that consists of an extracellular 
N-terminal ligand binding domain with a dimerization arm, a trans-membrane 
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domain and a C-terminal domain with a tyrosine kinase activity. ErbB receptors 
binds different ligands: EGF (epidermal growth factor), betacellulin (BTC), 
heparin binding EGF-like growth factor (HB-EGF), transforming growth 
factor-α (TGF-α), amphiregulin (AR), epiregulin (EPR), epigen (EPG) and 
neuregulins (NRG) (48). EGFR could bind different of these ligands: EGF, 
TGF-α, AR, BTC and EPR. EGFR ligands can induce the homodimerization of 
EGFR with HER1 and the heterodimerization with other member of the family: 
HER2, HER3 and HER4 (49). The extracellular domains of the EGFR are 
subdivided and numbered as I-IV. Several deletion mutations occur in the 
EGFR such as EGFRvI (AAΔ1–541), EGFRvIII (AAΔ6–273), EGFRvII 
(AAΔ521–603), EGFRvIV (AAΔ959–1053) and EGFRvV (AAΔ959–1186). 
Additionally, several point mutations occur in TK domain of EGFR (Fig.2).  
 Once EGFR have bound one of its ligands, the receptor dimerizes, and the 
tyrosine kinase domain of one receptor is able to induce the phosphorylation of 
specific tyrosine residues placed on the other receptor. These events are 
necessary to create a scaffold platform to recruit different effectors and docking 
proteins (50). The platform constituted by effectors and docking proteins 
associated to the activated receptor is able to recruits downstream signaling 
molecules thus causing the activation of different signaling cascades such as the 
Ras/Raf/mitogen-activated protein kinase pathway. This is a critically important 
route that regulates cell proliferation and survival through the MAPK 
extracellular signal-regulated kinases 1 and 2. Activated MAPKs are imported 
into the nucleus where they phosphorylate specific transcription factors 
involved in cell proliferation. EGFR activation is linked also to the PI3K/Akt 
pathway. This pathway is involved in cell growth, apoptosis resistance, 
invasion, and migration. EGFR interacts also with the src kinase pathways. src  
activates a series of substrates, including FAK, PI3K, and STAT proteins (51).  
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Fig. 2. The structure of EGFR (49). 
2.1.1. EGFR in cancer 
EGFR is a key factor in epithelial malignancies, and its activity enhances tumor 
growth, invasion, and metastasis. In cancer, EGFR is often perpetually 
stimulated because of the sustained production of EGFR ligands in the tumor 
microenvironment or as a result of a mutation in EGFR itself that locks the 
receptor in a state of continual activation or for gene amplification that results 
in protein overexpression. Though its altered activity has been studied primarily 
in development and growth of non-small cell lung cancer (NSCLC), many other 
tumors, including head and neck, ovary, cervix, bladder, esophagus, stomach, 
brain, endometrium, colon, breast, and liver are also known to exhibit 
deregulation of EGFR. 
Gene amplification of EGFR has been demonstrated to occur in different tumor 
types and it is usually associated with EGFR protein overexpression. In 
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glioblastoma multiforme (GBM), EGFR gene amplification has been found in 
37% to 58% of the tumors. Interestingly, a significant fraction of GBM (33%) 
with EGFR amplification showed multiple types of EGFR mutations. The most 
frequent variant of EGFR is the EGFRvIII, which accounts for more than 50% 
of the genomic alteration of EGFR observed in GBM. The EGFRvIII mutant 
receptor contains an in-frame deletion of exons 2-7 from the extracellular 
region that results in a truncated isoform of the receptor which unable to bind 
any ligands but, at the same time, the receptor is constitutively activated. 
Expression of EGFRvIII has been also described to occur in carcinomas such as 
breast and lung cancers (52). 
EGFR deregulation in cancer also occurs from point mutation in the tyrosine 
kinase (TK) domain. Most of this mutation has been identified in lung cancer 
and correlated with a better response to TK inhibitors (53). In ovarian cancer, 
EGFR expression and activation could contribute to aggressiveness of EOC 
cells through the promotion of cell proliferation, invasion, angiogenesis and 
escape from  apoptosis (54). EGFR was found amplified in about 4-22 % of 
ovarian cancer patients (55) and in about 4% of EOC cases activating mutations 
in the catalytic domain of EGFR were found (56). 
 
2.2 The Axl receptor 
Axl, also called Ark and Ufo, belongs to the TAM family which comprises also 
Tyro-3 (also called Sky) and Mer. The primary ligand for TAM receptors is 
growth arrest-specific 6 (Gas6), a fairly large (75 kDa) vitamin K–dependent 
protein known to activate downstream signalings (57). 
Axl is ubiquitously expressed and has been detected in a wide variety of organs 
and cells, including the hippocampus and cerebellum, monocytes, macrophages, 
platelets, ECs, heart, skeletal muscle, liver, kidney, and testis (58). 
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The N-terminal region of Axl undergoes to partial or complete glycosylation 
and the protein reaches the molecular weight of 120-140 kDa, respectively. 
The extracellular component of the Axl receptor contains two Ig-like domains 
followed by two FNIII domains. Between the FNIII domains and the C-terminal 
region of Axl there is a proteolytic cleavage site, yielding an 80 kDa soluble 
form of Axl (sAxl) which only comprises the extracellular domains of the full-
length protein (Fig. 3). The generation of sAxl involves the activity of 
disintegrin-like metalloproteinase 10 (ADAM10). A dynamic equilibrium 
between sAxl and Gas6 levels in biological fluids may have an important 
regulatory role and affect Gas6 function. The intracellular C-terminal region 
displays the highest level of conservation and comprises catalytic domains 
responsible for the kinase activity, which catalyses receptor 
autophosphorylation and tyrosine phosphorylation.  The interaction between 
Axl and Gas6 leads to the dimerization of Gas6/Axl complexes which results in 
autophosphorylation of tyrosine residues on the intracellular tyrosine kinase 
domain of Axl (59). 
Gas6/Axl signaling promotes growth, survival, and proliferation of numerous 
cell types by activation of two main signalling pathways: PI3K and 
RAS/RAF/MAPK/ERK1/2 signalling pathways. The Gas6/Axl/PI3K/Akt 
pathway protects cells from apoptosis via multiple mechanisms. Akt inhibits the 
pro-apoptotic role of the caspase 3 and phosphorylates NF-κB which increases 
the expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL (60).  In some 
cell types, Axl activates ERK and contributes to proliferation. Axl has been 
linked also to the modulation of the cell shapes and migration. Activation of 
p38 and phosphorylation of HSP25 (heat-shock protein 25), a regulator of actin 
remodelling, is downstream of Axl.  
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Fig. 3. Axl structure (59). 
The Axl-Nck2 (NCK adaptor protein 2) recruits Axl to a ternary complex 
composed by the particularly interesting new cysteine-histidine–rich protein 
(PINCH) and integrin-linked kinase (ILK), which are proteins necessary to FAs 
formation and migration (61).The Gas6/Axl pathway can inhibit other growth 
factor signals. Activation of the tyrosine phosphatase SHP-2 is responsible for 
Gas6/Axl-mediated VEGFR2 inhibition (62). Axl pathway increases the 
expression of suppressors of pro-inflammatory signals, SOCS1 and SOCS3, 
suppressing the inflammatory response (63). Taken together, Axl-dependent 
signalling is responsible for cell survival, migration and growth. Aberrant 
functions of the Gas6/Axl pathway are linked to cancer. 
 
2.2.1 Axl in cancer 
RTKs, including Axl, have been implicated in the pathophysiology of many 
cancers. Up-regulation of Axl has been reported in a variety of cancers 
including breast, gastric, prostate, ovarian, lung and other (58). 
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Overexpression of Axl was shown to correlate with poorer prognosis, as well as 
increased invasiveness and xenograft growth of human cancers. Axl was further 
shown to be a downstream effector of the EMT program, which is an enhancer 
of invasive mobility of malignant cells (64). 
Axl is over-expressed and activated in several drug-resistant cancer cell lines, 
suggesting that Axl may play a role in chemotherapy-resistant cancers. 
Increased Axl levels have been linked with Imatinib-resistant gastrointestinal 
stromal tumors, Nilotinib-resistant chronic myeloid leukemia cells, BMS-
754087(IKB kinase inhibitor)-resistant Rhabdomyosarcoma, Lapatinib-resistant 
HER-2 positive breast tumor cells and resistance to cisplatin in ovarian and 
esophageal adenocarcinoma (65). In melanoma, Axl-positive cells possessed a 
greater in vitro invasive potential compared with Axl-negative ones. Motility, 
invasivity, and ability to heal a wound or to migrate across an endothelial 
barrier were inhibited in vitro by Axl knockdown (66). In ovarian cancer, Axl 
and Gas6 overexpression was found in 90 cases, regardless of histopathological 
type or clinical stage of ovarian cancers (67) and the therapeutic blockade of 
Axl reduced the migratory and invasive capability of tumor cells in vitro and in 
vivo tumor xenografts (68). High levels of Axl mRNA were also reported in a 
cisplatin-resistant ovarian carcinoma cell line obtained by exposure to 
increasing concentrations of cisplatin. (69) 
Although Axl is consistently associated with resistance to chemotherapy and 
metastasis in cancer cells, the pathway downstream of Axl activation remain 
poorly defined. The emerging role of Axl in cancer holds potential for cancer 
treatment and therefore represents an important direction for future research. 
 
3. Crosstalk between adhesion molecules and RTKs in cancer. 
Tumorigenesis is a multistep process and reflects genetic alterations that drive 
the progressive transformation of normal human cells into highly malignant 
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derivatives. Nonetheless there are many types of cancer characterized by 
dfferent genetic aberrations and the activation of different signalling pathway, 
all cancer cells share some common hallmarks: self-sufficiency in growth 
signals, insensitivity to antigrowth signals, escape from apoptosis, sustained 
angiogenesis, tissue invasion and metastasis. In particular, migration, invasion 
and metastasis formation of tumor cells are responsible for most cancer-related 
mortality. Understanding how tumor cells acquire a migratory phenotype to 
become invasive and metastatic is crucial to develope effective strategies to 
block tumor progression. The first step in tumor cell invasion is the dissolution 
of cell-cell adhesions in favour of cell-matrix adhesions that support cell 
migration. Cells migrate in response to extracellular cues such as growth 
factors, which bind their RTKs at the cell surface. RTK activation initiates 
signalling cascades that contribute to the destabilization of cell-cell adhesions 
and promote migration by influencing the reorganization of the actin 
cytoskeleton often cooperating with integrins (70).  
 
3.1 Cadherins 
Cadherins are single pass transmembrane proteins that play crucial roles in 
normal development and in tissue homeostasis. They form Ca
2+
-dependent 
homophilic interaction for proper cell-cell adhesion. The main cadherin-based 
cell-cell adhesion structure is the Adherent Junctions (AJ). AJs are dynamic 
structures that physically connect neighboring epithelial cells, coupling 
intercellular adhesive contacts to the cytoskeleton. Infact, the intracellular 
domain of cadherins contains binding sites for the catenins p120 and β-catenin. 
p120 catenin links cadherin to microtubules and is also important to prevent 
cadherin endocytosis and degradation. β-catenin binds α-catenin, which in turn 
binds actin and several actin-associated proteins, including α-actinin, vinculin, 
and formin-1(71). 
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Change in the expression or localization of cadherins have been regularly 
associated with cancer.  It has been suggested that cadherins and RTKs cross-
signal each other in a way that the activation of one receptor leads to the 
activation or inactivation of the other receptor mediated pathway. It has been 
shown that RTKs activation leads to loss of cell-cell contacts by destabilizing 
cadherin-mediated adhesions. However, formation of cadherin-mediated 
adhesions inhibits RTK activity by decreased ligand binding, tyrosine 
phosphorylation and receptor mobility. In addition, the interaction might also 
result in co-internalization of cadherins and RTKs after ligand stimulation (72). 
The best characterized cadherin in tumors is E-cadh. Loss of E-cadh expression, 
reported in many types of tumors, is usually associated with a worst prognosis. 
Infact, loss of E-cadh leads to a more mesenchymal invasive and metastatic 
phenotype (73).  
It has been demonstrated that there is a bi-directional regulation of RTKs and E-
cadh For example, E-cadh was found to interact through its extracellular 
domain with EGFR thereby decreasing receptor mobility and ligand-affinity. 
On the contrary, low density cells showed a positive E-cadh- regulation on the 
EGF/EGFR signalling (74).  
EGFR activation has been linked with down-regulation of E-cadh-mediated 
cell-cell adhesion which results in increased tumor cell migration. This effect 
can be achieved by three different ways:  
1) Distruption of the E-cadh/catenin complexes, 
2) E-cadh endocytosis, 
3) Down-regulation of E-cadh expression. 
The presence of E-cadh has been shown to be important for the sensitivity to 
EGFR inhibitors for cancer therapy (75), thus studies into the mechanism of 
RTK/cadherin crosstalk in tumour cells could provide approaches for 
controlling invasiveness and resistance to current therapies. 
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3.2 Integrins 
Integrins are αβ heterodimeric transmembrane proteins implicated in numerous 
physiological processes including adhesion to the extracellular matrix, 
proliferation, survival, migration and differentiation. Integrins control signaling 
pathway that are usually deregulated in tumors, therefore they have a profound 
influence in cancer progression and numerous studies suggest that the 
cooperation between integrins and RTKs exists and exerts a central role in 
cancer progression regulating invasion, proliferation and survival (76). 
Considering that neither α or β subunit possess catalytic activity, it is possible 
that multiple mechanisms may regulate crosstalk between integrins and RTKs. 
Three main type of Integrins/RTKs interaction has been identified: 
1. Integrins can physically bind to RTKs.  
2. Integrins clustering can enhance signaling pathway that are activated 
also upon ligand-dependent RTKs activation. 
3. Integrins and RTKs reciprocally control their surface expression. 
α6β4 integrin directly associates with the ERBB2 receptor in breast cancer and 
enhances tumor formation and invasion (77).  
In pancreatic cancer, the iper-activation of EGFR leads to cancer metastasis but 
this process is dependent on the presence of αvβ5 integrin. On the other side, 
αvβ5 requires EGFR-mediated src activation to induce cell migration (78). 
In breast cancer cells, HGF binding to MET increases anchorage-independent 
growth by inducing the phosphorylation of β4 integrin resulting in the 
activation of src and ERK (79). 
The examples reported above are just a little portion of the increasing evidences 
regarding the central role of the integrins/RTKs crosstalk in cancer. The 
interaction between RTKs and integrins has made the last appealing as 
therapeutic targets for tumors that are responsive to particular growth factors. 
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4. The Epithelial Ovarian Cancer (EOC) 
EOC is the fifth leading cause of cancer death in women and is the most lethal 
gynaecological malignancy. The EOC is usually diagnosed when the tumor is 
already disseminated outside from the ovary because of the absence of specific 
clinical symptoms and marker for an earlier diagnosis. The plasma levels of the 
ovarian tumor antigen CA125 (Mucin16) is used for the follow up of the 
disease, but unfortunately it has not a sufficient specificity and sensitivity for 
population screening (80). The gold standard treatment for EOC is primary 
surgery, followed by adjuvant platinum-based chemotherapy with or without 
paclitaxel. Surgical debulking is an important prognostic factor and it is widely 
accepted that the volume of residual disease after primary surgery influences 
overall survival (OS). Despite an initial good response to the chemotherapy, 
recurrence is common and fatal. Therefore, research in the EOC field is devoted 
to achieve a better prevention, detection and screening methods.  
 
4.1 EOC classification 
EOC are heterogeneous neoplasms that are divided in: Type I and Type II on 
the basis of their molecular and clinopathologic features (Fig. 4). Type I tumors 
comprise low grade serous carcinomas (LGSCs), low-grade endometrioid, clear 
cell and mucinous carcinomas. They originate from precursor lesions, 
endometriosis such as borderline tumors. The borderline tumors, identified as 
low malignant potential (LMP), comprise a group of tumors characterized by 
cellular proliferation and nuclear atypia but without stromal invasion (81). Type 
I tumors are usually confined to one ovary, are indolents and with a good 
prognosis. 
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Fig.4. The histologic types of EOC and its associated genetic alterations (82). 
They constitute only 25% of EOCs with a 5 year survival of about 55%. Type I 
tumors are associated with frequent KRAS, BRAF, CTNNB, PTEN and PI3Ca 
genetic alterations, with rare mutations in TP53 gene. Type II tumors comprise 
high grade endometrioid and serous carcinomas (HGSCs) that are tumors with 
high cellular proliferation, frequent TP53 mutations (>90%) and genetic defects 
as mutations and inactivations in BRCA1 and BRCA2 genes. Type II tumors 
represent approximately 75% of all EOCs with a five year survival of about 
30% (82). 
. 
4.2. Pattern of spread of EOC 
The main characteristic of the EOC progression is that they rarely metastatize to 
distant sites but disseminate within the peritoneal cavity. Small clusters of 
cancer cells shed from the primary turmor, persist as free floating cells or multi-
cellular aggregates (MCAs) in the ascite and attach on the abdominal 
peritoneum or omentum (1) (Fig. 5). Tumor cells interact with mesothelial cells, 
placed in the inner surface of the peritoneal cavity giving secondary lesions to 
adiacent pelvic organs (83).  
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EOC originates from the ovarian surface epithelium (OSE) which invaginates 
into the underlying stroma resulting in inclusion cysts that eventually undergo 
malignant transformation (82). OSE cell integrity, unlike the other epithelia, is 
maintained by cell-cell adhesion through neural cadherins (N-cadh) expression; 
however E-cadh is expressed in the clefts and inclusion cysts (1). EOC 
normally displays both epithelial and mesenchymal characteristics retaining a 
high degree of plasticity, expressing vimentin together with cytokeratins 8 and 
18 (84). It was demonstrated that in EOC, E-cadh localization is maintained at 
cell-cell contacts during tumor progression and some advanced EOCs 
concomitantly express both E- and N-cadh (85). MCAs of the ascites present E-
cadh at the cell-cell contact. (86). In addition, while E-cadh expression is  
reduced in primary EOC, it could be re-expressed in metastatic lesions, where 
could sustain the survival of metastasis inhibiting apoptotic processes (87), 
suggesting that EOC cells undergo incomplete EMT. Interestingly, E-cadh 
engagement is necessary to the activation of PI3K/AKT-mediated proliferation 
(88), suggesting that E-cadh downstream signaling pathways could be 
Fig. 5. The metastatization of EOC (1). 
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important for EOC MACs growth. During the metastatic dissemination, the 
attachment and invasion of EOC cells into the mesothelial cell lining the 
peritoneal cavity, a process call mesothelial cell clearance, requires a 
mesenchymal gene expression program and the de-novo expression of integrins 
plays an important role (89).  Several groups have examined the ability of 
single EOC cells to pass through a mesothelial monolayer and found that the 
down-modulation of VCAM, α4 integrin, β1 integrin, MMP-2, or MMP-9 could 
decrease the extent of trans-mesothelial invasion. During the mesothelial cell 
clearance, mesenchymal genes appeared to be important, while epithelial genes, 
like E-cadh, were not associated to this process (90).  All these data argue for 
the notion that during the re-attachment of MCAs to the mesothelium, a switch 
from a proliferative to a more invasive signature happens and it is driven by the 
down-modulation of E-cadh expression and the de-novo expression of integrins. 
In this contest, the activation of RTKs and the cross-talk between RTKs and 
adhesion molecules appears an important step in EOC progression. 
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Aim of the Project 
The crosstalk between adhesion molecules and RTKs is considered an 
important driver in many types of cancers, including EOCs. Unfortunately, 
treatment with RTKs inhibitors resulted in a very poor clinical response in 
many type of tumors. For these reasons it is necessary to better investigate RTK 
signaling in tumor cells. A mediator of the crosstalk between adhesion 
molecules and RTKs is FAK. Deregulation of FAK correlates with increased 
survival, migration and invasion of cancer cells.  
FAK has been shown to be able to regulate RTK activation, cadherin 
localization and expression on the membrane surface and a mediator of the 
integrin signaling.  
Our aims are: 
1. To characterize a new role of FAK phosphorylated on Serine 732 (P-
FAKSer732) in tumors (section 1). 
2. To study the crosstalk between RTKs and adhesion molecules and the 
contribution of FAK to these processes. In particular, the study has been 
focused on: 
i. the crosstalk between E-cadh and EGFR (section 2), 
ii. the crosstalk between integrins and Axl (section 3). 
This study will contribute to identify new players that could be exploited to 
develop novel and more effective therapeutic approaches or as prognostic 
factors.
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Section 1 The involvement of P-FAKSer732 in proliferation of tumor cells 
Results and Discussion 
1.1 FAKSer732 is accumulated in dividing tumor cells, expressed in cancer 
cell lines and is not localized at the FAs during migration. 
First, we investigated on the localization of FAK in interphase migrating cells 
by immunofluorescence (IF) analysis. In particular, we analyzed whether a 
different FAK localization could be observed among P-FAKTyr397 (activating 
FAK site), P-FAKTyr576 (src-phosphorylated FAK site) and P-FAKSer732. 
We observed that, among all the phosphorylation of FAK, the P-FAKSer732 
was not localized at FAs site but mainly present in a perinuclear region while 
the tyrosine phosphorylation of FAK (-Tyr397 and –Tyr576) were present at 
the leading edge of migrating cells at the sites where FAs assembly and 
disassembly (Fig. 1a). Although the role of P-FAKSer732 has been already 
described in nuclear movement and neuronal migration (11) and in VEGF-
dependent endothelial cells migration (16), the first correlation between P-
FAKSer732 and cell mitosis came from A.Y. Park in 2009, but the role of P-
FAKSer732 has never been widely studied in cancer. In agreement with this 
previously literature knowledge, we also found that P-FAKSer732 was 
accumulated in mitotic cells (Fig. 1b). Seen the different localization, we then 
aimed to analyze if FAK phosphorylated on Ser732 was also phosphorylated at 
Tyr. We therefore performed an immunoprecipitaion (IP) with anti-P-
FAKSer732 antibody (ab) and the presence of FAK phosphorylated on Tyr was 
investigated on the unbound and immunoprecipitated fractions. P-FAKSer732 
in the immunoprecipitate was just poorly phosphorylated on Tyr576 while the 
dominant form in the unbound fraction contained P-FAKTyr576 (Fig. 1c). This 
result indicated that FAK could exist in two different pools on the bases of the 
type of phosphorylation and they might exert different roles. In several 
melanoma, ovarian and thyroid cancer cell lines, we tested the presence of P-
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FAKSer732 together with FAK phosphorylated on Tyr 576 (P-FAKTyr576), 
which is the phosphorylation site responsible for the maximum activation of the 
tyrosine kinase (5). We observed that, in all cell lines tested, P-FAKSer732 was 
expressed, although at variable levels (Fig. 1d). Moreover, there was no 
correlation between the levels of P-FAKSer732 and the activation of the kinase 
activity, showed by the levels of P-FAKTyr576.  
For the following analysis, the melanoma Me#28, the ovarian carcinoma 
OAW42 and the thyroid carcinoma NIM-1 cell lines were used as models. 
 
1.2 P-FAKSer732 is independent from integrin engagement and FAK 
kinase activity. 
Because P-FAKSer732 was not localized at the FA sites and is poorly 
phosphorylated on Tyr576, we investigated whether the phosphorylation at 
Ser732 residue was associated to integrin signalling cascade. To this aim, cells 
were grown 24 hr on plastic or fibronectin (fn). Western blot analysis on total 
cell lysates showed that the phosphorylation at Ser732 was not increased in 
cells grown on fn while P-FAKTyr397 and Tyr576 increased, as expected, in 
cells grown on fn (Fig. 2a).  To furher investigate whether FAK auto-
phosphorylation at Tyr397 was necessary for P-FAKSer732, Me#28 cells were 
transiently transfected with the mutant FAK construct named FRNK, which is a 
truncated isoform of FAK lacking the activation site (91) and the highest 
FRNK-expressing clone (F6) was selected by western blotting (Fig. 2b). Serum 
(FCS) stimulation of FRNK-transfected cells increased only P-FAKSer732 
while in mock-transfected cells increased P-FAKTyr397, -Tyr576 and -Ser732 
(Fig. 2c). Altogether these results indicated that the serine phosphorylation of 
FAK is independent from FAK kinase activity. 
Hence, FAK can exert in tumor cells a dual role: one integrin-dependent linked 
to migration and associated to phosphorylation of Tyr397 and -576, and the 
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other, characterized here for the first time, integrin-independent associated to 
phosphorylation on Ser732.  
The independence of P-FAKSer732 from integrin activation, its lack of 
localization at FA and its accumulation in dividing cells strongly suggest that, 
regardless of its involvement in migration, P-FAKSer732 play a role in the 
proliferation of tumor cells. 
 
1.3 P-FAKSer732 contributes to cell proliferation exerting a role in 
microtubules polymerization. 
To assess a role of P-FAKSer732 in proliferation, Me#28 cells were treated 
with a specific siRNA against FAK and growth capability was assayed. The 
growth rate of melanoma cells decreased 25% after 48 hr and up to 50% after 
72 hr (Fig. 3a). Furthermore, phosphorylation on Ser10 of Histone H3 (herein 
named PHH3), a marker of mitosis (92), was 30% lower in FAK-silenced cells 
in comparison with cells transfected with a control siRNA (Fig. 3b), suggesting 
a role of FAK in the control of the mitosis. To specifically assess a role of P-
FAKSer732 in cell proliferation, we transiently transfected, in control or FAK-
silenced Me#28 cells, a GFP construct containing a mutated FAK on 
Ser732→Ala10 (11) (herein named Mut GFP-FAK) or the corresponding wild-
type (wt) GFP-FAK. Control silenced cells transfected with Mut GFP-FAK 
displayed a reduction in the growth rate in comparison with those transfected 
with wt GFP-FAK that strongly decreased when Mut GFP-FAK was transfected 
into FAK-silenced cells (Fig. 3c).  These data argue for the hypothesis that P-
FAKSer732 is necessary to maintain the correct growth rate. 
The above reported results were further confirmed by western blotting of cell 
lysates from the transfectants described above. Both wt and Mut GFP-FAK 
showed a decrease of PHH3 (Fig. 3d), indicating a role in the entry in mitosis. 
Conversely, expression of the Mut GFP-FAK increased the amount of 
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acetylated α-tubulin (ac-α-tubulin) which is a well-conserved post-translational 
modification that marks long-lived microtubules present in the cytoplasm and in 
the mitotic spindle during mitosis, showing that this P-FAKSer732 could exert 
a function in the MT dynamics. 
  
1.4 P-FAKSer732 is localized at the mitotic spindle bound to tubulin and 
contributes to MTs dynamics.  
It was previously reported that in migrating neural cells P-FAKSer732 was 
responsible for the MT assembly to generate forces for nuclear movement (11). 
In ECs, P-FAKSer732 was associated to the centrosome contributing to mitotic 
spindle formation. Deletion of FAK in primary ECs causes increases in 
centrosome numbers, multipolar and disorganized spindles, and unaligned 
chromosomes during mitosis. Re-expression of wild-type FAK, but not the 
mutant isoform of FAK which lacks the Ser732 site, rescued these mitotic 
defects (17). P-FAKSer732 was also found associated with cytoplasmic dynein, 
which is a MT motor protein that plays a fundamental role in mitosis (93). 
Confocal IF was performed to better investigate on the localization of P-
FAKSer732 in dividing Me#28 cells. P-FAKSer732 co-localized with α-tubulin 
at the mitotic spindle during metaphase (Fig. 3a, left panel). During late 
anaphase, P-FAKSer732 co-localized with α-tubulin at the spindle, likely at the 
sites where MTs elongate and shrink (Fig. 4a, middle panel), and accumulated 
in the middle of the spindle, indicating an interaction with the cortical actin. 
Unlikely to what was reported previously by A.Y. Park, we didn’t find any co-
localization of P-FAKSer732 with the γ-tubulin at the centrosome (Fig. 4a right 
panel).  
Furthermore, we also found that P-FAKSer732 was co-localized with ac-α-
tubulin during all mitotic phases upon extraction of soluble tubulin (Fig. 4b) 
and it immunoprecipitated with both tubulin and dynein as previously reported,  
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assessing that dynein could be the mediator of the interaction between P-
FAKSer732 and MTs. (Fig. 4c). To analyze the role of P-FAKSer732 during 
mitotic spindle assembly, cell lysates from Nim-1 cells transiently transfected 
with the Mut GFP-FAK construct were analysed by western blotting. Mut GFP-
FAK showed an increased amount of polymerized MTs (2.5-fold), evaluated 
with anti- ac-α-tubulin ab, respect to cells that were transfected with a wt GFP-
FAK (Fig. 4d). These data indicate a possible role in MTs dynamics.  
To confirm this hypothesis, we performed a MT re-growth assay on Me#28 and 
OAW42 cells upon FAK silencing. Silenced cells were treated o.n. with 
nocodazole to force MT depolymerization, evaluated as the absence of ac-α-
tubulin, then, nocodazole washout was performed to investigate on MT re-
growth. FAK-silenced cells showed a higher amount of ac-α-tubulin indicating 
higher levels of polymerized MT and a better rescue of MT re-growth after 
nocodazole removal compared to cells transfected with control siRNA (Fig. 4e). 
These results clearly showed that P-FAKSer732 controls tumor cell 
proliferation by localizing at the mitotic spindle together with dynein and by 
exerting a role in MT polymerization. 
 
1.5 The lack of P-FAKSer732 impairs mitotic spindle formation and 
mitosis 
To specifically evaluate what could be the impact of the lack of P-FAKSer732 
in mitotic spindle assembly, wt and Mut GFP-FAK were transiently transfected 
in Me#28 and NIM-1 cells. In interphase, wt (Fig. 5a, left panel) and Mut GFP-
FAK (Fig.5b, left panel) were mainly localized at the sites of the FA, and no 
differences were observed between the two transfectants. In mitotic cells, wt 
GFP-FAK-transfected cells showed a regular spindle with wt GFP-FAK mainly 
localized on polar MTs (Fig. 5a, right panel). Interestingly, Mut GFP-FAK 
localized in randomly positioned spindle showing a diffused staining along the 
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entire spindle and the chromosomes appeared significantly unaligned (Fig. 5b, 
right panel). In agreement with these results, the number of mitosis was 6- and 
3-fold lower in Mut GFP-FAK transfected Me#28 and NIM-1 cells, 
respectively (Fig. 5c). 
 
1.6 The Cyclin-Dependent Kinase 5 is responsible for phosphorylation of 
FAK on Ser732. 
Cyclin-dependent kinase 5 (CDK5) is a peculiar proline-directed 
serine/threonine kinase that, unlike the other members of the Cdk family, is not 
directly involved in cell cycle regulation but mainly present in post-mitotic 
neurons and its activity is tightly regulated by the interaction with the specific 
activators, p35 and p39 (94). In neuronal cells, CDK5 is able to phosphorylate 
FAKSer732 (11). 
To test the hypothesis that CDK5 could be the kinase responsible for P-
FAKSer732, starved Me#28, OAW42 and NIM-1 cells were treated with 
increasing concentrations of roscovitine, a potent CDK5 inhibitor (95). 
Roscovitine treatment decreased the amount of P-FAKSer732 in a dose 
dependent manner in all cell lines (Fig. 6a), but did not affect the level of P-
FAKTyr397 and of P-ERK. Moreover, roscovitine treatment increased the 
amount of ac-α-tubulin in a dose-dependent manner. IF on roscovitine-treated 
NIM-1 cells showed impaired spindles and P-FAKSer732 staining was lower 
and diffused respect to that observed on untreated cells and no co-localization 
with acetylated α-tubulin was observed (Fig. 6b). These data demonstrated that 
CDK5 induces the phosphorylation of FAK at Ser732 independently from the 
FAK autophosphorylation thus contributing to spindle formation and mitosis of 
tumor cells. 
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1.7 The activation of the EGFR/MEK/ERK/CDK5 axis induces P-
FAKSer732. 
The EGFR is usually hyper-activated in many types of cancer. The MEK/ERK 
pathway is a downstream effector of EGFR (52) and in tumors, p35-dependent 
activation of CDK5 appeared to occur following ERK activation which in turn 
led to increased Egr1 transcriptional activity and up-regulation of p35 
expression (96). To assess whether P-FAKSer732 could be downstream to the 
EGFR/MEK/ERK/CDK5 axis, starved Me#28, NIM-1 and OAW42 cells were 
stimulated with EGF. In all the three cell lines, EGF stimulation increased P-
ERK together with P-FAKSer732 and P-CDK5Tyr15, the active kinase isoform 
(Fig. 7a). To test whether CDK5 was downstream of EGFR/MEK/ERK 
signaling cascade, ERK2 siRNA treated Me#28 cells were stimulated with 
EGF. EGF stimulation strongly increased P-FAKSer732 and P-CDK5Tyr15 of 
control siRNA-treated cells but not of ERK2 silenced cells showing that, upon 
EGFR activation, the phopshorylation of FAKSer732 induced by CDK5 needs 
the activation of the MEK/ERK pathway (Fig. 7b). 
 
Conclusion and future perspectives 
The results collected in this section present a deep analysis on the role of P-
FAKSer732 in tumor cells. We have found that the phosphorylation of FAK at 
Ser732 occurs independently from integrin activation, is not localized at the 
sites of FAs and accumulates in mitotic cells. P-FAKSer732 plays a role in 
mitosis thus regulating the proliferation of tumor cells controlling the mitotic 
spindle assembly. We found that the phosphorylation of FAKSer732 was 
downstream of the EGFR/MEK/ERK pathway and we identified CDK5 as the 
kinase responsible for this phosphorylation.  
In solid tumors, P-FAKSer732 is necessary for MT depolymerization thus 
maintaining normal, therefore not malignant, spindle assembly and function. 
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CDK5 is localized mainly in neurons and its presence, together with the 
presence of P-FAKSer732, should be analyzed in a large panel of solid tumors 
with the aim to correlate these two molecules with the malignancy and therefore 
with tumor growth or resistance to chemotherapy. The involvement of FAK in 
the mitotic spindle assembly requires further investigation to evaluate the 
possibility to develop specific inhibitors to this particular FAK function. 
Moreover, the link between EGFR activation and P-FAKSer732, never 
demonstrated before, could allow a better understanding of the role of the 
EGFR in cancer that might be useful to design alternative therapeutic approach 
in tumors become resistant to anti-EGFR compounds. 
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Section 2 The crosstalk between RTKs and adhesion molecules and the 
contribution of FAK and E-cadh to these processes 
Results and Discussion 
During the progression of EOC, tumor cells detached  from the primary tumor, 
persist as free-floating cells or MCAs which are able to escape from anoikis, 
and re-attach to a secondary site giving metastases (97). An uncontrolled 
integrin-independent activation of FAK responsible for the escape from anoikis 
in tumor cells has been already reported (41). In the previous section, we 
showed that the proliferation of tumor cells is strongly dependent on the 
presence of the EGF-induced P-FAKser732 that control mitotic spindle 
assembly through the binding to MTs mediated by the cytoplasmatic dynein. E-
cadh expression is unusually up-regulated in EOC. It is not expressed in normal 
OSE cells, but is expressed in pre-malignant lesions and in well-differentiated 
tumors where it is membrane-associated as component of the AJs (98). E-cadh 
is also co-expressed with N-cadh in late-stage invasive tumors. In our lab, it 
was previously found that E-cadh knockdown impairs cell-cycle progression 
and proliferation of EOC cells and that the E-cadh-mediated AJ formation 
contributes to PI3K/AKT activation (88). 
Here, we focused our attention on the role of FAKSer732 in EOC and in 
particular in MCAs biology and on the role exerted by the crosstalk between 
EGFR and E-cadh in this contest.  
 
2.1 P-FAKSer732 is present in fresh EOC ascites together with E-cadh and 
the CDK5 activators p35 and p25. 
With the aim to assess if P-FAKSer732 could be activated in EOC MCAs, we 
checked for its presence in several fresh EOC cells from ascites by western 
blotting. The characteristics of these ascites used are reported in Table I. 
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We also analyzed the presence of cell-cell adhesion components such as N-cadh 
and E-cadh together with the expression of CDK5 whose function has been 
reported in the previously section and in Rea K. et.,al 2013 (99).We found P-
FAKSer732 expressed in 7 out of 8 EOC cells from ascites analyzed and 5 of 
them also co-expressed E-cadh. Seven out of 8 expressed CDK5 and its 
activators p35 and p25 (Fig. 8a). These findings were also confirmed by IF 
analysis on sample #7 where the EOC MCAs were positive for P-FAKSer732, 
p35 and E-cadh staining (Fig. 8b). 
 CDK5, a cyclin dependent kinase, is a widely expressed protein but its role in 
cell cycle control is not reported (100). Its activation depends on non-cyclin 
proteins, named p35 and p39, and the phosphorylation of CDK5 on Tyr15 
increases its kinase activity. p35 and p39 resemble cyclins in their 3D structures 
and are almost exclusively detected in the nervous system (101). Recently, non-
neuronal function of CDK5 has been also reported (102). Calpain is the 
mediator of the cleavage of p35 into p25. Although the levels of p25 are 
generally low in tissues, the interaction between CDK5 and p25 promotes 
CDK5 stability and enhances its kinase activity, resulting in the abnormal 
phosphorylation of substrates such as tau (94). In line with this data, we found 
p25 expressed in almost all the ascites analyzed, indicating an uncontrolled 
activation of CDK5. 
In order to set up a 3D culture model resembling in vitro EOC MCAs, the EOC 
cell lines SKOV3 and OVCAR5 cells were seeded in the non-adhesive 
substrate   alginate scaffold, the AlgiMatrix™. Alginate scaffold, to which 
integrins of human cells do not bind, allows the formation of spheroids and 
enables to study cell-cell adhesion. After 10-12 days of cultures, the MCAs 
were collected, fixed or lysated and analyzed by IF or by western blotting, 
respectively. As shown in Fig. 8c, both cell lines formed MCAs similar to those 
found in the EOC ascites (upper panel) and up-modulated E-cadh at the cell-cell 
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contacts (lower panel) respect to cells grown as monolayer (2D). Indeed, the 
western blotting showed that in 3D culture, E-cadh was de novo expressed in 
SKOV3 cells (Fig. 8d), and increased in OVCAR5 cells together with an 
increased level of P-FAKSer732 in both cell lines analyzed respect to cell 
grown on 2D. 
To assess if in vivo the E-cadh/P-FAKSer732 axis could be present exclusively 
in floating MCAs, we performed a western blotting on total cell lysates 
obtained from two mouse xenograft models of human EOC. EOC cells from 
human ascites are usually injected in the peritoneum of the mice and about two 
months later, the mice are sacrificed and tumor cells are collected from ascites 
and from the solid masses grown attached to the peritoneal organs. We show 
here a western blotting performed on the lysates obtained from each tumor 
samples, the EOC MCAs from the ascites and the solid counterpart. As 
hypothesized, P-FAKSer732 was expressed only in the MCAs from ascites 
(Asc) in the 2 samples analyzed, while it was absent in the solid counterpart (st) 
(Fig. 8e). These observations were confirmed since P-FAKSer732 was present 
at higher levels in MCAs and less expressed in the solid tumors from 2 EOC 
patients (Fig. 8f). 
Altogether the results suggest that E-cadh could be a determinant of MCAs 
formation and maintenance of P-FAKser732 levels. 
Based on these results and those reports in the previous section, the possible 
existence of a crosstalk between the mechanism of cell-cell adhesion, mediated 
by E-cadh, and the EGFR/MEK/ERK/CDK5/P-FAKSer732 axis will be further 
investigated. 
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2.2. E-cadh induces FAKSer732 phosphorylation by modulating the CDK5 
activation and CDK5 is necessary to stabilize E-cadh at the cell membrane. 
It has been already showed that, upon integrins engagement, the activation of 
src and FAK leads to AJs disruption. Phosphorylation of β-catenin by FAK 
results in a loss of AJ integrity following integrin engagement (103). FAK can 
also regulate AJs by controlling the stability of E-cadh protein levels (22). An 
increased expression of E-cadh has been observed in FAK-null mouse 
embryonic cells, which was attributed to the regulation of the E-cadh 
transcriptional repressor SNAIL1 (104). FAK can also regulate the endocytosis 
of E-cadh and thereby its membrane localization. Depletion of FAK or β1-
integrin, inhibits E-cadh endocytosis and is associated with a strengthening of 
cell–cell adhesions and reduced collective invasion (105). 
With the aim to assess if a  cooperation between the E-cadh signalling and the 
EGFR/MEK/ERK/CDK5/P-FAKSer732 axis exists, starved OAW42 cells were 
transfected with a pool of two specific E-cadh (siE-cadh) or  control siRNA and 
a western blotting was performed on total cell lysates. As showed in Fig. 9a, E-
cadh-silenced cells showed the decrease of P-FAKSer732 and P-CDK5tyr15, 
without affecting the other phosphorylation of FAK and the levels of P-ERK. 
Moreover, the E-cadh silencing also reduced the levels of the marker of mitosis 
PHH3 indicating that E-cadh expression has a role in cell proliferation. 
To test if, as previously reported, the knockdown of FAK could have a role in 
modulating the expression of E-cadh influencing also the E-cadh-dependent 
CDK5 activation, OAW42 cells were treated with an E-cadh siRNA (siE-cadh) 
or with a FAK siRNA (siFAK) or with a control siRNA. Surprisingly, the 
western blotting performed on total cell lysates from the cells described above 
showed that FAK depletion affected neither the levels of E-cadh nor the levels 
of P-CDK5Tyr15 and the silencing of both, E-cadh plus FAK, did show a slight 
additive effect on the inhibition of CDK5 activation (Fig. 9b). Therefore, the 
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activation of CDK5/P-FAKSer732 axis depends on the presence of E-cadh. 
However, E-cadh protein stability is FAK independent in EOC cells. 
In addition, because E-cadh silencing affects the activation of CDK5 (showed 
by the decreased levels of P-CDK5Tyr15) without affecting the levels of P-
ERK, we speculated that direct connection between E-cadh and CDK5 could 
exist and it could be enhanced by the EGFR activation. In corneal epithelial 
cells, it has been already reported that CDK5 is localized in E-cadh containing 
epithelial cell-cell adhesions and co-immunoprecipitates with E-cadh (106).  To 
test in EOC a biochemical interaction between E-cadh and CDK5, we 
performed an IP with anti-CDK5 ab on total cell lysates obtained from serum 
starved OAW42 cells stimulated or not with EGF. The western blotting 
confirmed that E-cadh is physically bound to CDK5 and that the amount of E-
cadh/CDK5 complexes increased upon EGF stimulation (Fig. 9c). To study the 
meaning of the physical interaction between E-cadh and CDK5, OAW42 cells 
were treated with a CDK5 siRNA (siCDK5) or with a control siRNA (siCO) 
and IF was performed. In siCO cells, E-cadh was localized on the cell 
membrane at the sites of stable AJs. Upon CDK5 silencing, the stability of E-
cadh at the cell membrane was impaired, as showed by the diffuse staining of 
E-cadh in the cytoplasm of silenced cells (Fig. 9d). In addition, CDK5 silenced 
cells showed longer MTs, confirming that CDK5 has a role in MTs dynamics 
that is mediated by P-FAKSer732 (as showed in section 1 and in Rea K. et 
al.,2013). 
 
2.3 EGFR/E-cadh/CDK5 multi-protein complex regulates EGFR signaling 
pathway. 
To assess if a multi-protein complex, constituted by EGFR/E-cadh/CDK5, 
could be present in MCAs complexes, we also performed an IP with anti-E-
cadh in lysates obtained by in vitro culture of starved OAW42 cells grown in 
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AlgiMatrix™ and stimulated or not with EGF. The western blotting confirmed 
that E-cadh is also physically bound to EGFR and that the amount of E-
cadh/EGFR complexes increased upon EGF stimulation (Fig. 10a) arguing for 
the hypothesis that a multi- protein complex composed by EGFR/E-cadh/CDK5 
exists. With the aim to assess if the physical association among EGFR/E-
cadh/CDK5 could influence EGFR activation, western blotting was performed 
on total cell lysates from starved siE-cadh or control-transfected OAW42 cells 
treated or not with the CDK5 inhibitor, roscovitine, upon EGF stimulation for 
30 min. As showed in Fig. 10b, upon EGF stimulation control-transfected cells 
showed increased levels of P-EGFRTyr1068, which is the EGF-dependent 
autophosphorylation site, together with that of P-FAKSer732 and P-
CDK5Tyr15. The phosphorylation levels of each protein were reduced in E-
cadh-silenced cells and strongly impaired when E-cadh-silenced cells were 
treated with roscovitine (Fig. 10b). Interestingly, both E-cadh silencing and 
roscovitine treatment reduced the levels of EGFR arguing for the hypothesis of 
a regulation of EGFR stability by the E-cadh/CDK5 activation. Therefore, E-
cadh regulates the EGF-dependent activation of the EGFR/CDK5/P-
FAKSer732 axis. 
Next, we aimed to test if E-cadh expression gives an increased sensitivity to 
roscovitine treatment. Two E-cadh positive (OAW42 and OVCAR5) and two 
E-cadh negative (SKOV3 and NL3507) cell lines were treated with roscovitine 
for different time point to perform a cytotoxicity assay. The results showed that 
the two E-cadh-positive cell lines were more sensitive to roscovitine respect to 
E-cadh negative cell lines (Fig. 10c, left panel and Fig. 10c right panel that 
shows the relative amount of E-cadh in each cell lines analyzed by western 
blotting). 
Altogether these results confirm that E-cadh directly regulates P-FAKSer732 by 
the modulation of CDK5 activity in a manner that E-cadh may stabilize EGFR 
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expression and activation thus contributing to cell proliferation. The E-cadh/P-
FAKSer732 could also be used as a signature identifying patients that will be 
responsive to CDK5 inhibitors. 
 
Conclusion and future perspectives 
In this section, we found that the expression of E-cadh in EOC could be an 
important feature during EOC progression contributing to cell proliferation and 
survival by the crosstalk with EGFR and the CDK5-mediated P-FAKSer732. 
As showed in section 1, P-FAKSer732 exerts an important role in MT 
polymerization and mitotic spindle formation thus modulating mitosis. 
Although, we found that P-FAKSer732 is independent from cell-ECM 
adhesion, in the current section we showed that it is dependent on E-cadh 
mediated cell-cell adhesion. EOC is the fifth leading cause of cancer-related 
deaths among women, and the leading cause of death from gynecological 
cancer. During EOC progression, small clusters of cancer cells shed from the 
primary tumor survive and proliferate as free floating cells. Subsequently these 
MCAs attach on the abdominal peritoneum giving a secondary lesion (97). This 
particular behaviour argues for the hypothesis that cell-cell and cell-ECM 
adhesion can contribute to mechanisms of proliferation/survival and of 
migration/invasion. We found that EOC cells, purified from ascites, express E-
cadh at cell-cell contact. These EOC cells also expressed P-FAKSer732 and 
p35, the CDK5 activator. Because we found E-cadh is involved in modulating 
the EGFR/CDK5/P-FAKSer732 and, previously, our group demonstrated that 
E-cadh contributes EOC cell growth by recruitment of the PI3K-p85 subunit to 
the cell membrane (88) while P-FAKSer732 contributes to cell proliferation by 
regulating mitotic spindle formation (99), we can speculate that both signallings 
cooperate leading to growth and maintenance of MCAs present in the malignant 
ascites.  
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We introduced here some important steps in this complex scenario that clarified 
some mechanisms of MCAs biology. 
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Section 3 The crosstalk between  RTKs and adhesion molecules and the 
contribution of FAK to these processes: the role of Axl. 
Results and Discussion 
As reported in the section “State of Art”, a critical step in ovarian cancer 
metastasis is the transition of EOC cells from a proliferative to a more invasive 
phenotype necessary to establishing secondary lesion within the peritoneal 
cavity (107).  
The MCAs present in the ascites form a reservoir of cancer cells that 
continuously re-populate the abdominal cavity leading to metastasis. The re-
attachement to the peritoneal cavity requires that the MCAs loss cell-cell 
adhesion contacts and express de-novo integrins such as αvβ3 integrin, 
secretion of ECM component such as fn (107) and metalloproteases such as 
MMP-2 (108). All these events are induced by multiple biochemical changes 
that enable cells to assume a mesenchymal phenotype, which includes enhanced 
migratory capacity and invasiveness. These molecular changes are the basis of 
the EMT (109). MCAs can attach and spread on multiple ECM proteins 
associated with the mesothelium and then they need to pass through (or “clear”) 
the mesothelial cells and take contact with the underlying basement membrane. 
This process is known as mesothelial clearance (89).  In a recent study, EOC 
cell lines were divided in mesothelial clearance competent or incompetent cells 
on the basis of a mesenchymal gene expression profile which was positively 
correlated with clearance competency. Axl was one of the genes correlated with 
the clearance competency (90). Axl is a member of the TAM family of RTKs 
which is composed of three members: Axl, Mer, and Tyro-3. Axl has not a 
prominent role as oncogenic driver but it has been found overexpressed in many 
type of cancers and related to cancer progression (58).  
The exact mechanisms that allow cells to undergo to EMT and to secondary 
lesions are largely unknown. 
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 In this scenario, the roles of the TAM receptor and the ligand Gas6 have been 
investigated. 
 
3.1 The expression of Gas6 and TAM receptor in EOC stable cell lines. 
As first, we checked the expression of Gas6 and the three TAM receptors in a 
panel of human EOC cell lines by RT-PCR and western blotting. OVCAR4, 
and SKOV3 cells expressed the highest levels of Gas6 (Fig. 11a), while 
OVCAR5 and NL3507 barely showed detectable Gas6 transcript. The 
expression of the three TAM receptors was heterogeneous with Axl expressed 
at high levels in OVCAR5, NL3507 and SKOV3 cells as resulted by both real 
time RT-PCR and western blotting (Fig. 11a and b). 
 
3.2 Axl is the TAM receptor specifically activated by the Gas6. 
To assess which TAM receptors was activated by Gas6 stimulation,  an IP with 
an anti-phosphotyrosine ab (p-Tyr) was performed on starved SKOV3 cells, 
expressing the TAM receptors Axl and Tyro-3, and on starved NL3507 cells, 
expressing Axl and Mer, stimulated or not with Gas6. In both starved cell lines, 
Axl was already slightly tyrosine phosphorylated compatible with stimulation 
by endogenously produced Gas6, and de novo Gas6 stimulation induced higher 
levels of Axl phosphorylation (Fig. 12a). In SKOV3 cell, a slight amount of 
phosphorylated Tyro-3 was observed, while in NL3507 neither Mer nor Tyro-3 
resulted tyrosine phosphorylated upon Gas6 stimulation. 
In line with these results, in both Gas6-stimulated cell lines the phosphorylation 
of Axl was inhibited by the presence of a recombinant Axl-Fc protein (Fig. 
12b).  
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3.3 Gas6 and sAxl expression in EOC ascites  
Next, we aimed to investigate on both the presence of Gas6 and Axl in EOC 
ascites. We therefore analyzed 22 EOC ascites by ELISA and found that the 
levels of Gas6 ranged from 43 to 103ng/ml with a mean value of 74.1ng/ml and 
were statistically higher compared to levels in 22 ascites from non-malignant 
pathologies (Fig 13a and Table II for the main characteristics of the ascites 
used). To evaluate if the soluble Axl ectodomain (sAxl) is able to sequester 
Gas6, its levels were also measured. As shown in Fig. 13b, Axl molecules were 
not sufficient to completely sequester Gas6 molecules in 20 out of 22 ascites 
indicating that Gas6 present in the EOC ascites was available for the 
stimulation of TAM receptors eventually expressed by EOC cells.  In oral 
squamous cell carcinoma (OSCC) Gas6 released from the tumor-associated 
macrophages (TAMs) has been shown to promote tumor metastasis through the 
activation of Axl (110). As observed in OSCC, the presence of Gas6 in EOC 
ascites suggests that it acts like a fuel, maybe released by EOC cells or by the 
cells of the the immune system present in the microenvironment, favoring 
tumor invasion and the establishment of secondary lesions. 
 
3.4 The Gas6/Axl activation doesn’t affect cell proliferation but is involved 
in cell migration and actin cytoskeleton remodeling and invasion. 
Once assessed that Axl and its ligand Gas6 were expressed in EOC cells and 
that Gas6 specifically actives Axl, we next aimed to get information about their 
functions. 
A role for Gas6/Axl in proliferation of normal lens epithelial cells (111) and in 
proliferation of prostate human carcinoma (112) and colon cancer (113) has 
been already reported. We performed a proliferation assay on Gas6-stimulated 
SKOV3 transfected with a control siRNA (siCO) or with an Axl siRNA (siAxl) 
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showing that Gas6-dependent Axl activation didn’t affect cell proliferation in 
EOC (Fig. 14a). 
Following, we tested whether Gas6 was able to induce cancer cell migration by 
wound healing assay performed on starved SKOV3 and NL3507 cells upon 
Gas6 stimulation. Wounds were created in cell monolayers, and the wound 
repair was recorded at different time point post-wounding. Gas6-stimulated 
SKOV3 cells repaired the wound after 30 hr, while, at the same time, starved 
SKOV3 cells only showed 39% of wound repair. NL3507 cells repaired 21% of 
the wound after 30 hr in presence of Gas6 and only 10% in serum-free 
condition (Fig. 14b). 
Next, we investigated whether the Gas6-dependent Axl activation leads to 
cytoskeleton remodeling by IF performed on starved SKOV3 and NL3507 cells 
in presence or not of Gas6.  In both cell lines Gas6 stimulation led to membrane 
protrusion formation in a sheet-like conformation, such as lamellipodia, 
induced by actin polymerization at the leading edge (Fig. 14c lower panel) that 
were not visible in serum starved cells (Fig. 14c upper panel). Filopodia-like 
structures were also observed at the migrating front of cells together with large 
focal adhesions (Fig. 14c lower panel). These results demonstrated that 
Gas6/Axl pathway induces EOC cell migration through the remodeling of the 
actin cytoskeleton. 
 
3.5 The Gas6/Axl pathway enhances cancer cell invasion. 
To assess whether The Gas6/Axl signaling could be involved also in cancer cell 
invasion, we performed reduced growth factor matrigel-embedded 3D cultures 
of SKOV3 and NL3507 cells, to drive the formation of spheroids, with the aim 
to resemble the invasion process occurring in vivo. After 5 days, single cells 
from both EOC cell lines were able to form spheres in matrigel (Fig. 15a, left 
panels). These spheroids were serum-starved and stimulated or not with Gas6 to 
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evaluate its effect on cell behavior. Gas6 stimulation of the spheres induced the 
formation of a stellate invasive phenotype characterized by invadopodia and 
chains of cells that invade through the surrounding matrigel (Fig. 15a, right 
panel). To test if the interaction with component of the ECM was essential in 
the Gas6-induced invasion, we used the AlgiMatrix™, to which human 
integrins do not interact. SKOV3 spheroids, grown in AlgiMatrix™ for 12 
days, were serum starved and stimulated or not with Gas6. Opposite to what we 
observed in matrigel, Gas6 did not induce any morphological change (Fig. 15b, 
left panel).  These spheres were then taken from AlgiMatrix™, embedded in 
matrigel and stimulated or not with Gas6, as above. An invasive morphology 
was observed only in the presence of Gas6 (Fig. 15b, right panel). 
These results indicate that Gas6 stimulation alone is not sufficient to induce cell 
invasion but it needs the interaction with the ECM.  
Moreover, we found that, in starved SKOV3 and NL3507 cells allowed to 
adhere for a short time (30 min) on fn coated dishes, the levels of Axl activation 
upon Gas6 stimulation, reported as the level of Axl phosphorylated on Tyr702 
(P-AxlTyr702) analyzed by western blotting, were higher in cells adherent on 
fn respect to cells simply adherent on plastic as explained by the quantitative 
analysis of three independent experiments reported in the graph (Fig. 15c upper 
and lower panels). These results showed that the interaction with ECM and the 
integrin engagement could enhance Gas6-mediated Axl activation.  
Among the different β chain of the integrin molecules, SKOV3 and NL3507 
cells express the integrin β3, as assessed by FACS analysis (Fig. 15d, upper 
panel). To assess in NL3507 whether indeed this integrin was involved in Gas-
stimulated Axl activation, the previous experiment was performed in the 
presence of an ab able to inhibit integrin β3/fn interaction. As expected, the 
inhibition of the integrin β3 to bind the ECM protein completely abolished 
Gas6-induced Axl tyrosine phosphorylation (Fig. 15d, lower panel). 
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These data showed that, in EOC, the activation of Gas-stimulated Axl signaling 
pathway is dependent on the interaction with the ECM.  
 
3.6 The Gas6-dependent activation of Axl requires the cross-signal with 
integrins mediated by the scaffold protein p130cas.  
The synergism between RTKs and integrins is mediated by intracellular 
scaffold proteins, such as FAK and p130Cas, which integrate both signaling 
leading to the intracellular response (9). To study if these scaffold proteins 
could be the mediator(s) between Gas6/Axl and integrin/ECM signallings, the 
possible interaction between Axl and p130Cas or FAK was analyzed by IP 
performed on starved SKOV3 stimulated or not with Gas6. Total cell lysates 
were immunoprecipitated with anti-p130Cas (Fig. 16a) or-FAK Abs (Fig. 16b) 
and the obtained protein complexes were analyzed by western blotting with 
anti-Axl ab. We found that Axl co-immunoprecipitated with the p130Cas 
scaffold protein in absence and in presence of Gas6 (Fig 16a), while it only 
slightly interacted with FAK (Fig. 16b).  
p130Cas is a scaffold protein involved in the process of cell adhesion and 
migration upon integrin engagements with the ECM (114). In EOC, high 
p130Cas expression has been reported to be associated with advanced tumor 
stage and inversely associated with overall survival and progression-free 
survival (115). 
To test if p130Cas could be essential for Gas6-dependent activation of Axl, 
SKOV3 were transiently silenced for p130Cas (sip130Cas) or with a control 
siRNA, plated on fn coating or on plastic, serum starved and then stimulated or 
not with Gas6. Upon Gas6 stimulation, control silenced cells showed, as 
expected, an increased level of phosphorylated Axl respect to cells in serum-
free medium (Fig. 16c). Interestingly, both starved and Gas6-stimulated fn 
adherent cells showed higher levels of Axl phosphorylation respect to cells 
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adherent on plastic. These results showed that Gas6 requires the synergism 
between Axl and integrins which is mediated by the intracellular scaffold 
proteins p130Cas. 
 
3.7 Altering p130Cas/Axl interactions reduces Gas6-dependent adhesion 
and invasion.  
To further clarify the role of p130Cas in the Gas6-dependent Axl activation and 
its contribution to EOC cell interaction with the ECM, the mechanism of cell 
adhesion was analyzed. To this aim, SKOV3 cells were transiently silenced for 
p130Cas (sip130Cas) or with a control siRNA (siCO), plated on fn and the cell 
adhesion was monitored up to 1 h by live imaging in presence or not of Gas6. 
Upon Gas6 stimulation, siCO cells started to adhere on fn after 10 min and after 
20 min were completely spread on the substrate while Gas6-stimulated 
sip130Cas cells were not yet adherent on fn at the same time point (Fig.17a left 
panel) but same number of cells resulted adherent to fn in starved siCO cells 
and in sip130Cas cells stimulated with Gas6 (Fig. 17a right panel) meaning that 
the p130Cas-silenced cells were not activated by Gas6. 
To further investigate on the cellular effect of p130Cas in the Gas6-dependent 
Axl activation, starved sip130Cas or control transfected SKOV3 cells were 
plated on fn and IF analysis of actin cytoskeleton was performed in presence or 
not of Gas6. Upon Gas6 stimulation, siCO cells plated on fn showed the 
formation of filopodia-like structure, while p130Cas-silenced cells appeared 
rounded and not attached to the substrate (Fig 17b).  
To assess if the presence of p130Cas is necessary also in Gas6/Axl mediated 
cell invasion, stable control or p130Cas-silenced SKOV3 cells (Mock- and 
shp130Cas-SKOV3, respectively) were then embedded in reduced-growth 
factor matrigel and the obtained spheroids were then stimulated or not with 
Gas6.  Upon Gas6 stimulation, shp130Cas-SKOV3 cells maintained a spherical 
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shape, while Mock-SKOV3 spheroids formed structures that invade into the 
surrounding thick matrigel (Fig. 17c). 
These data strongly indicated that in the Gas6-dependent integrin-dependent 
adhesion, p130Cas is essential for invasion into ECM of EOC cells. 
 
3.8 Gas6/Axl signaling triggered PI3K/AKT/rac activation. 
In order to better clarify the downstream signaling pathway which is 
responsible for Gas6/Axl-dependent migration and invasion, SKOV3 were 
Gas6 stimulated while adhering to fn and the actin assembly was evaluated by 
IF with labeled phalloidin. Gas6 induced protrusive structures at the leading 
edge associated to the presence of stress fibers (Fig. 18a). In the presence of the 
compounds R428, an inhibitor of Axl phosphorylation, actin nucleation was 
inhibited as well as the formation of stress fibers. Interestingly, treatment of fn-
adherent SKOV3 cells with the rac inhibitor EHT1864 recapitulated the effect 
of the Axl inhibitor on actin assembly and formation of stress fibers. Western 
blotting on total lysates from the same treated cells showed that R428 inhibited 
Axl and AKT phosphorylations (Fig. 18b). The phosphorylation of the src 
kinase, known to be activated by the adhesion to ECM proteins, resulted 
increased upon adhesion on fn and did not increase upon Gas6 stimulation, but 
it slightly increased in R428 treated cells only, arguing for the hypothesis that 
Axl activation could partially inhibit ECM-dependent src activation. On the 
other hand, rac inhibitor could decrease src phosphorylation but not Gas6-
dependent AKT phosphorylation.  
These results were further supported by inhibition of the invasion of Gas6-
stimulated SKOV3 spheroids in matrigel by both the Axl and rac inhibitors 
(Fig. 18c).  
Altogether these data suggest that Gas6/Axl signaling led to PI3K/AKT/rac 
activation in ECM-adherent EOC cells in a src-independent way. 
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3.9 Validation of the Gas6/Axl signaling in “in vivo” EOC samples. 
The results obtained highlighted that the Gas6/Axl axis could be very important 
in metastasis formation. To test Gas6/Axl signaling also in in vivo samples, 
EOC MCAs were allowed to adhere on matrigel in presence or not of Gas6 and 
cancer cells invasion into matrigel was monitored by phase contrast 
microscopy. Accordingly to that observed for EOC cell lines, Gas6 induced in 
EOC MCAs morphological transformation such as the acquisition of a stellate 
invasive phenotype (Fig. 19a). An IP performed with an anti-p130Cas ab on a 
MCA lysates confirmed that, Axl is physically bound to p130Cas also in vivo 
(fig. 19b). 
Accordingly, immunohistochemistry (IHC) on an archival case material showed 
that, among 72 EOC primary tumors, the majority expresses Axl at the cell 
membrane (80%) (Table III). Eighty % of these EOC samples also co-expressed 
p130Cas in the cytoplasm (representative samples in Fig.19c).  
In particular, Axl and p130Cas co-expression could distinguish type I from type 
II EOCs as evaluated by Fisher’s Exact Test (p=0,0009, Fig. 19d). These data, 
together with the biochemical and cellular data obtained in vitro, argue for the 
notion that EOCs susceptible to Gas6 activation are only those co-expressing 
Axl and p130Cas and that the Gas6/Axl signaling cascade is activated 
preferentially in p130Cas-expressing type II EOCs. 
 
Conclusion and future perspectives 
This section uncovers a new role of Gas6/Axl pathway during the progression 
of EOCs. The main novelties are: 1) the founding that Gas6, present at high 
levels in EOC ascites, is involved in EOC cell migration and invasion 2) the 
assessment that Gas6/Axl signaling requires an integrin-dependent pathway 
mediated by the scaffold protein p130Cas for activation.  
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In oral squamous cell carcinoma (OSCC) Gas6 released from the tumor-
associated macrophages (TAMs) has been shown to promote tumor metastasis 
through the activation of Axl (110). Accordingly with these previous 
observations, we showed that Gas6/Axl pathway was able to promote cell 
invasion in integrin-dependent fashion. We also outlined that the crosstalk 
between integrins and Axl was mediated by a direct interaction with p130Cas 
but not with FAK. In fact, the p130Cas knocking-down reduced the capability 
of EOC cells to invade into matrigel and inhibited the cytoskeleton remodeling 
observed upon Gas6 stimulation. In line with our results, high p130cas 
expression was previously found in EOC and it was associated with advanced 
tumor stage and inversely associated with overall survival and progression-free 
survival (115). It is widely reported the role of p130Cas in regulating cell 
invasion through the release of matrix metalloproteinases such as MMP-9 
(116). In EOC, Axl activation has been linked with cell invasion through the 
induction of MMP-1 and MMP-9 (68). Our results indicate that high levels of 
Gas6 in the EOC microenvironment activates actin re-organization and in turn 
adhesion and invasion. These functions are mediated by the interaction between 
Axl and p130Cas. We also demonstrated that all these processes downstream of 
Gas6/Axl/p130Cas axis are driven by the PI3K/Akt/rac activation. 
All together, our experimental data suggest that Gas6/Axl/p130Cas axis is 
involved in EOC dissemination and metastasis formation.  
A larger analysis of the expression of Gas6, Axl and p130Cas is ongoing in 
EOC and preliminary data indicate that the presence of an activated 
GAS6/Axl/p130Cas signaling pathway could be exploited as an indicator of an 
invasive EOC phenotype. The possibility to discriminate among different EOC 
phenotypes through the identification of new molecules that play a key role in 
the different step of EOC progression, as the Gas6/Axl/p130Cas axis, could 
lead to new and more specific therapeutic approaches. 
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The exploitation of therapeutic strategies targeting each of these molecules 
might be successful in the inhibition of EOC dissemination, especially for those 
patients, resistant to the conventional chemotherapies, who unfortunately recur 
with uncontrolled dissemination. 
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Fig. 1. FAKSer732 is accumulated in dividing tumor cells, expressed in cancer cell lines 
and is not localized at the FAs during migration. 
 a. IF performed on starved Me#28 cells induced to migrate through a wound. Cells were 
stained for P-FAKSer732, -Tyr 397, -Tyr 576, FAK (green) and α-tubulin (red). Nuclei were 
stained with DAPI (blue). Merged images are reported on the upper panels. b. IF performed on 
fixed cells upon FCS stimulation with anti-P-FAKSer732 ab (green). Nuclei were stained with 
DAPI (blue). c. IP performed with anti-PFAKSer732 ab on total cell lysates obtained from 
Me#28 cells. Normal rabbit (IgG) sera was used as negative control. Immunoprecipitated and 
unbound samples were analyzed by western blotting. d. Western blotting performed on total 
cell lysates from melanoma (n=14), ovarian (n=9) and thyroid (n=3) cancer cell lines. β-actin 
was used as control of gel loading. 
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Fig. 2. P-FAKSer732 is independent from integrin engagement and FAK kinase activity. 
a. Left panel: western blotting performed on total cell lysates from starved Me#28 cells grown 
on plastic (-) or fibronectin (fn). α-tubulin was used as control of gel loading. Right panel: 
densitometric analysis reporting the levels of FAK phosphorylated isoforms respect to total 
FAK expression of cells grown on fn. The medium values of three experiments are reported. 
Asterisk, p≤0.05. b. Western blotting performed on total cell lysates of the clones obtained from 
FRNK-transfected (Me)#28. The clone F6, expressing the highest levels of FRNK protein, was 
selected for the experiment reported on Fig. 2c. c. Western blotting performed on total cell 
lysates from Mock- or FRNK-transfected (clone F6) Me#28 cells. β-actin was used as control of 
gel loading.  
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Fig. 3. P-FAKSer732 contributes to cell proliferation exerting a role in microtubules 
polymerization. 
a. Proliferation assay performed on cells transiently transfected with control- (siCO) or FAK- 
(siFAK) siRNA. Representative growth curves of one of three independent experiments are 
shown; each point represents the mean of four replicates. Error bars, SD. b. Mitotic index 
performed on control- (siCO) or FAK- (siFAK) silenced (Me)#28 cells. The level of mitosis is 
reported as the percentage of PHH3 positive cells measured by FACS. Asterisk, p≤0.05. c. 
Proliferation rate of control- (siCO)- or FAK- (siFAK)-silenced Me#28 cells transfected with wt 
or Mut GFP-FAK vectors. The experiment was done three times in quintuplicate. The 
percentage of proliferation rate was calculated normalizing the values of each sample with those 
obtained in cells transfected with the GFP-containing vector only. Asterisks indicate statistical 
significant values (p˂0.001). Error bars, SD. d. Western blotting performed on total cell lysates 
of the transfectants described above. β-actin was used as control of gel loading. Endogenous 
FAK, thin arrow, ectopic FAK, thick arrow.  
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Fig. 4. P-FAKSer732 is localized at the mitotic spindle bound to tubulin and contributes to 
MTs dynamics.  
a. Confocal IF performed on fixed Me#28 cells with anti-P-FAKSer732 and ac-α- (left and 
middle panels) or γ-tubulin abs (right panel). Images of metaphases (left and right panels, 
section 14 and 12, respectively) and late anaphase (section 11, middle panel) are shown. Bars, 
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10µm. b. IF performed on (Me)#28 cells upon extraction of free tubulin. The white arrows 
indicate the mitotic phases: 1, prophase; 2 anaphase; 3, telophase; 4, cytokinesis. The 
immunostaining was performed with anti-P-FAKSer732 (red) and ac-α-tubulin (green) abs. 
Nuclei were stained with DAPI (blue). Bars, 60µm. c. IP performed with anti-P-FAKSer732 
(S732) and -dynein intermediate chain abs on lysates from Me#28 cells. Normal rabbit or 
mouse (IgG) sera were used as negative control. Immunoprecipitated samples were analyzed by 
western blotting. d. Upper panel: western blotting performed on total cell lysates from NIM-1 
cells transfected with GFP alone, wt or Mut GFP-FAK vectors. Endogenous FAK, thin arrow, 
ectopic FAK, thick arrow. Lower panel: densitometric analysis performed on the western 
blotting shown in the upper panel. The results of an experiment of three performed are shown. 
e. MT re-growth assay was performed on Me#28 and OAW42 cells transiently transfected with 
control (siCO) or FAK (siFAK) siRNA. MTs were depolymerized treating the cells with 5 
μg/ml nocodazole in complete medium at 37 °C o.n. Cells were washed with complete medium 
once and incubated at 37 °C. For Me#28 and OAW42 cells, the MT re-growth was allowed for 
30 min and 3 h, respectively. Total cell lysates were analyzed by western blotting. β-actin was 
used as control of gel loading. 
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Fig. 5. The lack of P-FAKSer732 impaires mitotic spindle formation and mitosis. 
Me#28 and NIM-1 cells transiently transfected with wt (a) or Mut GFP-FAK (b) vectors. IF 
was performed with anti-α-tubulin (red) ab on fixed cells. Nuclei were stained with DAPI 
(blue). Inserts on the bottom report green/red merge showing the localization in the spindle of 
the exogenous wt or Mut GFP-FAK. Bars, 10µm. c. Number of mitosis in transfected cells. 
Error bars, SD. Asterics indicate p≤0.05. 
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Fig. 6 The Cyclin-Dependent Kinase 5 is responsible for phosphorylation of FAK on 
Ser732. 
a. Western blotting performed on total cell lysates from starved Me#28, OAW42 and NIM 1 
cells untreated or treated with roscovitine (2-20 µM) and stimulated with FCS. β-actin was used 
as control of gel loading. b. Confocal IF performed on fixed NIM-1 cells untreated or treated 
with roscovitive (10µM) and stained with anti-P-FAKSer732 (green) and α-tubulin (red) abs. 
Bars, 20µm. 
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Fig. 7. The activation of the EGFR/MEK/ERK/CDK5 axis induces P-FAKSer732. 
a. Western blotting performed on total cell lysates from starved Me#28, NIM-1 and OAW42 
cells stimulated with EGF (20 ng/ml) for up to 20 min. β-actin was used as control of gel 
loading. b. Western blotting performed on total cell lysates from Me#28 cells silenced with 
control (-) or ERK2 (+) siRNA, starved and then stimulated with EGF (20 ng/ml) for 15 min. α-
tubulin was used as control of gel loading. 
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Fig. 8. P-FAKSer732 is present in fresh ascites together with E-cadh and the CDK5 
activators p35 and p25. 
a. Western blotting performed on total cell lysates from cells of EOC ascites. β-actin was used 
as control of gel loading. b. IF performed on cells of EOC ascites sample #7. The 
immunostaining was performed with anti-E-cadh, anti-P-FAKSer732 and anti-p35/p25 (green) 
abs. Nuclei were stained with DAPI (blue). c. Upper panel: phase contrast microscopy 
performed on SKOV3 and OVCAR5 cells grown on AlgiMatrix™. Lower panel: IF performed 
on fixed cells upon scaffold dissolution. The immunostaining was performed with anti-E-cadh 
(green) ab. Nuclei were stained with DAPI (blue). d. Western blotting performed on total cell 
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lysates from SKOV3 and OVCAR5 cells grown on plastic (2D) or AlgiMatrix™ (3D).  β-actin 
was used as control of gel loading. e. Western blotting performed on total cell lysates from cells 
of two human EOC ascites and the corresponding solid tumors obtained by two mouse 
xenograft tumors. OAW42 lysates were used as positive control. β-actin was used as control of 
gel loading. e. Western blotting performed on total cell lysates from cells of two EOC matched 
samples: ascites and the tumor cells from the corresponding solid tumors. β-actin was used as 
control of gel loading. 
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Fig. 9. E-cadh induces FAKSer732 phosphorylation by modulating the CDK5 activation 
and CDK5 is necessary to stabilize E-cadh at the cell membrane. 
a. Western blotting performed on total cell lysates from OAW42 cells transiently transfected 
with control (-) or E-cadh (siE-cadh) siRNA. β-actin was used as control of gel loading. b. 
Western blotting performed on total cell lysates from OAW42 cells silenced with control (-) or 
E-cadh (siE-cadh) or FAK (siFAK) siRNA. α-tubulin was used as control of gel loading. c. IP 
performed with anti-CDK5 ab on lysates from starved or EGF-stimulated OAW42 cells. 
Immunoprecipitated samples were analyzed by western blotting. d. IF performed on fixed 
OAW42 cells transiently transfected with control- (siCO) or CDK5- (siCDK5) siRNA. Cells 
were starved and then stimulated with EGF (20 ng/ml) for 30 min. The immunostaining was 
performed with anti-E-cadh and ac-α-tubulin (green) abs. Nuclei were stained with DAPI 
(blue). 
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Fig. 10. EGFR/E-cadh/CDK5 multi-protein complex regulates EGFR signaling pathway.  
a. IP performed with anti-E-cadh ab on lysates from starved or EGF-stimulated OAW42 cells 
grown on AlgiMatrix™.  Immunoprecipitated samples were analyzed by western blotting. b. 
Western blotting performed on total cell lysates from OAW42 transiently transfected with a 
control (-) or E-cadh (siE-cadh) siRNA, starved, treated with roscovitine and then stimulated 
with EGF (20 ng/ml) for 30 min. β-actin was used as control of gel loading. c. Left panel: 
NL3507, OAW42, SKOV3 and OVCAR5 cells were treated with roscovitine up to 96 hr and 
cell viability was measured by CellTiter-Glo® Luminescent Cell Viability Assay. 
Representative growth curves of one of three independent experiments are shown; each point 
represents the mean of three replicates. Error bars, SD. Right panel: Western blotting performed 
on total cell lysates from NL3507; OAW42; SKOV3 and OVCAR5 cells. β-actin was used as 
control of gel loading. 
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Fig. 11. The expression of Gas6 and TAM receptor in EOC stable cell lines. 
a. Real-time PCR for Gas6, AXL, MERTK, and TYRO-3 genes of total RNA from six EOC 
cell lines. Results are presented as relative expression normalized to GAPDH mRNA levels. b. 
Western blotting performed on total cell lysates from the same six EOC cell lines. β-actin was 
used as control of gel loading. 
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Fig. 12. Axl is the TAM receptor specifically activated by the Gas6. 
a. IP performed with Anti-P-Tyrosine (P-Tyr) ab on lysates from starved or Gas6-stimulated 
SKOV3 and NL3507 cells. Immunoprecipitated samples were analyzed by western blotting. b. 
Western blotting performed on total cell lysates from starved SKOV3 and NL3507 cells pre-
treated with Axl-Fc (2.5 μg/ml) and stimulated or not with Gas6.  β-actin was used as control of 
gel loading. 
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Fig. 13. Gas6 and sAxl expression in EOC ascites. 
a. Gas6 levels measured by ELISA on 22 EOC ascites and 22 non malignant ascites. b. 
Evaluation in the EOC ascites of the sequestration by Axl ectodomain of Gas6. The graph 
reports the molar ratio between Gas6 and Axl ectodomain (sAxl). The red line represents the 
equimolar ratio. 
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Fig. 14. The Gas6/Axl activation doesn’t affect cell proliferation but is involved in cell 
migration and actin cytoskeleton remodeling and invasion. 
a. Proliferation assay performed on SKOV3 cells transiently transfected with control (siCO) or 
Axl- (siAxl) siRNA. Representative growth curves of one of three independent experiments are 
shown; each point represents the mean of four replicates. Error bars, SD. b. Wound-healing 
assay performed on starved SKOV3 and NL3507 upon GAS6 stimulation. Upper panel: 
representative images reporting the wounds at the starting point (T=0 hr) and at the end of the 
experiment (T=30 hr). Lower panel: wound-healing repair capability at 30 h from the scratch. 
Asterisks p=0.01. Error bars, S.D. c. IF performed on starved SKOV3 and NL3507 induced to 
migrate through a wound in presence or not (-) of Gas6. F-actin was stained with phalloidin. 
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Fig. 15. The Gas6/Axl pathway enhances cancer cell invasion. 
a. Invasion assay of starved (-) or Gas6-stimulated SKOV3 and NL3507 cells grown in 
Matrigel®. b. Left panel: phase contrast microscopy performed on starved (-) or Gas6-
stimulated SKOV3 cells grown on AlgiMatrix™. Right panel: the spheres were dissolved from 
the AlgiMatrix™ and passed in Matrigel® in presence or not (-) of Gas6. c. Upper panel: 
western blotting performed on total cell lysates from starved or Gas6-stimulated SKOV3 and 
NL3507 cells seeded on fn for 30 min. A representative experiment of three performed is 
shown. β-actin was used as control of gel loading. Lower panel: quantitative evaluation of 
phosphorylated Axl in Gas6-stimulated cells upon adhesion on fn. The graph reports the 
mean±SD from three independent experiments. D. Upper panel: membrane staining of the 
integrin β3, β1 and β4 receptor was determined by flow cytometry on NL3507 cell line. The red 
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and light blue peaks, respectively, represent the fluorescence of the cells incubated with the 
secondary antibody alone as control (α-mouse) and the anti-integrins ab.  Lower panel: western 
blotting performed on total cell lysates from starved or Gas6-stimulated NL3507 cells, in the 
absence or in the presence of the anti-integrin β3 ab. A representative experiment is shown. β-
actin was used as control of gel loading.  
Focal Adhesion Kinase involvement in modulating the proliferation of tumor cells. 
75 
 
a
c
b
TOTTOT
- +              - +          - +                 - +   Gas6
IP:Anti-p130Cas IP:IgG
Axl
p130Cas
TOTTOT
- +              - +          - +                 - +   Gas6
IP:Anti-FAK IP:IgG
Axl
FAK
- - - - +         +        +        +    Gas6  
tubulin
P-AxlTyr702
- +         - +          - +         - +    Sip130Cas  
FN
p130cas
FN
 
 
Fig.16. The Gas6-dependent activation of Axl requires the cross-signal with integrins 
mediated by the scaffold protein p130cas.  
IP performed with anti-p130Cas (a) or with anti-FAK (b) abs on lysates of starved or Gas6- 
stimulated SKOV3 cells. Normal mouse or rabbit (IgG) sera were used as negative control, 
respectively. Immunoprecipitated samples were analyzed by western blotting. c. Western 
blotting performed on total cell lysates from SKOV3 cells transiently transfected with control or 
p130Cas (sip130Cas) siRNA. Cells were starved and seeded on fn for 30 min in presence or not 
of Gas6. α-tubulin was used as control of gel loading. 
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Fig.17. Altering p130Cas/Axl interactions reduces Gas6-dependent adhesion and invasion.  
a. Left panel: live cell imaging performed on starved (-) or Gas6-stimulated (+) control- (siCO) 
and p130Cas- (sip130Cas) silenced SKOV3 cells during adhesion on fn.  Representative frames 
at 0, 10’ and 20’ hr are reported; frames were taken up to 1 hr. Right panel: graph reporting the 
number of siCo- or sip130Cas-silenced SKOV3 cells adherent on fn at different time point in 
presence or not of Gas6. b. IF performed on starved (-) or Gas6-stimulated siCo- or sip130Cas-
silenced NL3507 cells upon 20 min of adhesion on fn. The F-actin was stained with phalloidin. 
c. Invasion assay performed on starved (-) or Gas6-stimulated SKOV3 cells stably p130Cas-
silenced (shp130Cas) or transfected with a control shRNA (Mock) and then grown in 
Matrigel®. 
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Fig.18. Gas6/Axl signaling triggered PI3K/AKT/rac activation. 
a. IF performed on SKOV3 cells grown on fn, starved and then induced to migrate through a 
wound in presence or not of Gas6. Cells were treated with the reported inhibitors and F-actin 
was stained with phalloidin (red). b. Western blotting performed on total cell lysates from 
starved or Gas6-stimulated SKOV3 cells seeded on fn and treated with the reported inhibitors. 
A representative experiment of three performed is shown. β-actin was used as control of gel 
loading. c. Invasion assay performed on starved or Gas6-stimulated SKOV3 and NL3507 cells 
grown in Matrigel®. Cells were treated with the reported inhibitors. 
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Fig.19. Validation of the Gas6/Axl signaling in “in vivo” EOC samples. 
a. Invasion assay performed on starved (-) or Gas6-stimulated EOC MCAs from two 
representative Axl-positive ascites grown in matrigel. b. IP performed with anti-p130Cas ab on 
total cell lysates obtained from the EOC of patient #1. A normal mouse (IgG) serum was used 
as negative control. Immunoprecipitated samples were analyzed by western blotting. c. 
Representative images of anti-Axl and anti-p130Cas abs staining on FFPE EOC sections. Scale 
bar, 50 μm. d. Graph reporting the correlation between p130Cas and Axl expressions in Type I 
and Type II EOC. Contingency analysis was performed by Fisher’s exact test, p=0,0009. 
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Table 1. Characteristics of the EOC samples evaluated in the present study. 
 
Sample 
ID 
Histotype Grading FIGO
a
Stage 
Presence 
of tumor 
cells
b
 
1 Serous G2 III Abundant 
2 Serous G3 III Present 
3 Mixed G3 III Abundant 
4 Serous G3 III Abundant 
5 Undifferentiated Undifferentiated III Abundant 
6 
c
 NA III Present 
7 Serous G2 III Present 
8 Serous  G3 III Abundant 
a  
Federation of Gynecologists and Obstetricians. 
 
b  
The amount of cells present in ascites of EOC patients as defined  
c
  Endometrial cancer with metastasis to the ovary as subsequently evaluated by 
the pathologist. 
NA, not applicable. 
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Table 2. Characteristics of the EOC patients evaluated in the present study. 
 
 
Sample 
ID 
 
Histotype 
 
Grading 
 
 
FIGO
a
 
Stage 
Presence of: 
Tumor cells
b
 
Mesothelial 
cells
b
 
1 Serous G3 IV Abundant Present 
2 Serous G3 IIIC Abundant Present 
3 Serous G3 IIIC Abundant Present 
4 Serous G3 III Rare Present 
5 Serous G3 IIIC Abundant Abundant 
6 Serous G3 IIIC Present Present 
7 Serous G3 IIIC Rare Abundant 
8 
Serous and 
endometroid 
G3 IV Abundant Present 
9 Serous G3 IIIC Abundant Rare 
10 
Mullerian 
mixed 
NA IIIC Present Abundant 
11 Serous G3 IIIC Rare Present 
12 Serous G2 IIIC Abundant Present 
13 Serous G2 IIIC Abundant NA 
14 Serous G3 IIIC Rare Abundant 
15 Endometroid G3 IV Rare Abundant 
16 Serous G3 IIIC/IV Present Abundant 
17 Serous G3 IV Abundant Rare 
18 Endometroid NA IIIC Present Abundant 
19 Serous NA IIIC Abundant Rare 
20 Serous G3 IIIC Present Present 
21 Serous G2/G3 IIIC Abundant Rare 
22 Serous G3 IIIC Abundant Present 
 a 
Federation of Gynecologists and Obstetricians. 
 
b
The amount of cells present in ascites of EOC patients as defined by the 
cytopathologist at diagnosis. 
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Table 3. Clinicopathological characteristics of EOC biopsies evaluated by IHC with the Abs 
anti-Axl and –p130Cas. 
 
Clinicopathological 
characteristics 
Total 
(%) 
AXL 
positive 
cases (%) 
AXL 
negative 
cases  
p130 cas  
positive 
cases (%) 
p130 cas  
negative 
cases (%) 
Tumor stage                   
I 19 26.39 12 63.16 7 36.84 13 68.42 6 31.58 
II 6 8.33 5 83.33 1 16.67 4 66.67 2 33.33 
III 47 65.28 41 87.23 6 12.77 42 89.36 5 10.64 
Tumor grade     
 
  
   
  
  1 10 13.89 5 50 5 50 5 50 5 50 
2 23 31.94 16 69.57 7 30.43 20 86.96 3 13.04 
3 37 51.39 35 94.59 2 5.41 32 86.49 5 13.51 
Undifferentiated 2 2.78 2 100 0 0 2 100 0 0 
Histologic subtype     
 
  
   
  
  LGEC 4 5.56 3 75 1 25 3 75 1 25 
MOC 10 13.89 2 20 8 80 3 30 7 70 
COC 2 2.78 2 100 0 0 2 100 0 0 
HGSC 51 70.83 46 90.2 5 9.8 46 90.2 5 9.8 
HGEC 3 4.17 3 100 0 0 3 100 0 0 
Undifferentiated 2 2.78 2 100 0 0 2 100 0 0 
Tumor Type     
 
  
   
  
  Type I 16 22.22 7 43.75 9 56.25 8 50 8 50 
Type II 56 77.78 51 91.07 5 8.93 51 91.07 5 8.93 
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